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INTRODUCTION 
 Cryptococcus neoformans is an encapsulated heterobasidiomycetous fungus that 
has progressed from being a rare human pathogen to become a common worldwide 
opportunistic pathogen in immunocompromised hosts75. Although the name Cryptococcus 
literally means “hidden seed”, the hitherto less known pathogen came into limelight with 
the advent of the AIDS pandemic. The genus Cryptococcus comprises of over 70 species 
but human infection is seldom caused by species other than C.neoformans and C.gattii 47. 
Occasional cases of infections due to C.laurentii (Lynch et al, 1981)59, C.albidus 
(Horowitz et al, 1993)35 and C.adeliensis (Rimek et al, 2004)83 have been reported but 
isolation of other cryptococcal species from clinical specimens requires both culture and 
histological proof of invasion before attributing disease to them. In general, C.neoformans 
is associated with infection in immunocompromised hosts while C.gattii is associated with 
infections in immunocompetent hosts76.  
The spectrum of human cryptococcosis varies broadly from asymptomatic 
colonization of the respiratory tract to widespread disseminated infection. Cryptococcal 
meningoencephalitis (CM) is the most severe, life threatening clinical presentation 
requiring immediate antifungal therapy in affected patients. CM is an AIDS defining 
condition in patients infected with HIV and generally occurs when the CD4 count falls 
below 100 cells /µl76. During the early 1990s, about 5-15% of patients with AIDS suffered 
from CM which accounted for almost 2/3rd of all culture proven cases of meningitis. 
Although the incidence of CM has declined in developed countries due to widespread use 
of HAART and prophylactic medications; CM still continues to be the leading cause of 
meningitis in HIV patients in developing countries. At present, the global burden of CM as 
estimated by CDC is 1 million new cases/ yr with about 1,33,600 cases occurring in South 
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east Asia43. According to recent WHO estimates, cryptococcosis accounts for 13-44% of 
deaths in HIV infected cohorts in resource limited countries81. Even with optimal 
treatment, the 10 week mortality rate of HIV associated CM is high ranging from 10-25% 
and reaches upto 65% in resource poor settings.12, 39,74 In Sub-Saharan Africa alone, >5, 
00,000 deaths occur each year due to Cryptococcus which may exceed those attributed to 
tuberculosis82. In India, the prevalence of meningitis due to Cryptococcus in HIV patients 
has shown a remarkable decline from 45-60% in the beginning of 21st century to 3-16% by 
the beginning of this decade93.            
C.gattii which has long been considered to infect only immunocompetent hosts has 
started to cause infections in AIDS patients adding to the burden of cryptococcal infection 
in this cohort .14, 17 Since neurological complications are more with C.gattii, identification 
of this species needs to be prioritized. An additional concern is the emergence of drug 
resistance in Cryptococcus to antifungal agents in recent years48. Though the reports are 
sparse, routine testing for antifungal susceptibility testing of clinical isolates is necessary 
to obtain baseline data and observe any shift in sensitivity pattern. 
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AIMS AND OBJECTIVES 
1. Rapid identification of Cryptococcus as the etiologic agent of meningitis in HIV 
positive patients using microscopic techniques and latex agglutination test 
 
2. Isolation of Cryptococcus in culture from the CSF of the affected patients and also 
from  other sites (in cases of disseminated infection)  
 
3. Speciation of the cryptococcal isolates using phenotypic methods 
 
4. Determination of susceptibility pattern of cryptococcal isolates to antifungal agents 
and comparison of MIC values obtained by E- test with those of  microbroth 
dilution method 
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REVIEW OF LITERATURE 
HISTORY  
The first isolation of Cryptococcus from the environment was in 1894 by Sanfelice 
who recovered encapsulated yeast from peach juice and named it as Saccharomyces 
neoformans. In the subsequent year, Otto Busse & Buschke independently reported the 
isolation of yeast from a 31yr old woman in Germany with an ulcer over her tibia77. 
Buschke called the organism Saccharomyces subcutaneous tumefaciens. However 
Vuillemin transferred the yeast to the genus Cryptococcus in 1901 as he did not find 
ascospores characteristic of Saccharomyces in the isolate and named it as C.hominis. In 
1905, Van Hansemann observed Cryptococcus in a case of meningitis and described the 
presence of yeast in gelatinous cysts in his post mortem report. Verse in 1914 recognised 
Cryptococcus antemortem in a case of leptomeningitis in a 29yr old woman. Cutler and 
Stoddard in 1916 delineated the clinical and pathologic differences between 
cryptococcosis, blastomycosis and other mycoses. They erroneously assumed that the 
capsule of the organisms were cysts in the tissue caused by digestive action of the fungus 
and named the organism Torula histolytica and the disease was known for a long time as 
Torulosis77. As most of the cryptococcal isolates were initially from Europe, the clinical 
entity of cryptococcosis was referred as European Blastomycosis too. Rhoda Benham in 
1935 attempted to categorise 27 isolates of pathogenic cryptococci based on morphology, 
fermentation and serological studies75. She concluded that there was only one species and 
suggested retaining the name Cryptococcus hominis. In 1952 Lodder and Kreger Van Rij 
emphasised the priority of the name C.neoformans which finally became the accepted 
name. In 1976, Kwon-Chung discovered and characterized the sexual stage of 
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C.neoformans and the teleomorph was named Filobasidiella neoformans51. In 2003, the 
genome of C.neoformans was sequenced. 
TAXONOMY 
 Cryptococcus genus is placed in the Fungi Kingdom under the Phylum 
Basidiomycota, Subphylum Basidiomycotina, Class Urediniomycetes, Order Sporidiales 
and Family Sporidiobolaceae. Traditionally 5 serotypes of Cryptococcus neoformans have 
been described based on variation in the capsular epitopes75. The serotypes are 
characterized using antibodies from rabbit sera or specific monoclonal antibodies. For 
several decades, serotypes A. D & AD were included under var. neoformans and serotypes 
B & C under var. gattii75. The varietal status was accorded on the basis of differences in 
biochemical tests. With the advent of molecular era it became evident that serotypes A and 
D significantly diverge from each other. Franzol et al in 1999 proposed to separate these 
serotypes into 2 varieties based on differences in URA5 gene sequences30 (coding for 
orotidine monophosphate pyrophosphorylase). Using a variety of genetic analyses, Xu et 
al estimated that the A and D serotype separated from each other more than 18 million 
years ago95. Now serotype A has been distinguished as a new variety, var. grubii and 
serotype D has been retained under var. neoformans. The varietal status for AD serotypes 
is unclear but evidence states that they probably represent hybrids between serotypes A 
and D. In 2006 Cryptococcus gattii was accorded separate species recognition based on 
significant differences in the ecology and epidemiology. Therefore, C.neoformans is 
currently classified into 2 varieties (var.grubii and var. neoformans) and C.gattii is its 
sibling species58. 
 The taxonomic classification of these varieties and serotypes has been further 
updated through new genomic analysis. On the basis of DNA sequence polymorphisms 
 detected by PCR fingerprinting, RAPD, AFLP, RFLP and MLST analyses, 
and C.gattii have been further subdivided into 9 distinct molec
isolates produce VNI, VNII, or VNB (Botswana)
pattern and serotype D isolates produce VNIV pattern. Serotype B isolates yield VGI, 
VGII and VGIII patterns while serotype C isolates yield predominan
pattern. 
C.neoformans
C.gattii
6 
ular types
 pattern; AD hybrids produce VNIII 
tly a VGIII or VGIV 
Serotype A 
(var.grubii)
VNI
VNII
VNB
Serotype AD
VNIII
Serotype D
(var. neoformans) VNIV
Serotype B
VGI
VGII
VGIII
Serotype C
VGIII
VGIV
C.neoformans 
58
. Serotype A 
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LIFE CYCLE 
Cryptococcus neoformans can exist in two distinct life cycles- asexual and 
sexual77. In the asexual stage, it exists as encapsulated yeast cells and reproduces by 
simple, narrow based budding. These unicellular haploid yeasts are the primary forms 
recovered from both environmental sources and human infections. However, as a 
heterothallic basidiomycete, Cryptococcus neoformans can undergo transition to a hyphal 
growth form by 2 different differentiation mechanisms- Mating and Monokaryotic 
fruiting.  
 
 
 
 
 
 
 
 
 
 Yeast forms of Cryptococcus neoformans exist in one of the two mating types: a or 
α. Mating in Cryptococcus was discovered more than three decades ago by Kwon- Chung 
and involves fusion of haploid cells of opposite mating types to produce dikaryotic 
hyphae. Under nutrient limiting conditions, a and α yeast cells secrete peptide pheromones 
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that trigger cell- cell fusion. The resulting dikaryon initiates hyphal growth and a septum 
forms to separate the cells. These hyphae bear true clamp connections. During the 
formation of basidium, the 2 nuclei fuse and undergo meiosis to produce meiotic products. 
This results in the formation of 4 chains of basidiospores by mitosis and the uninucleate 
basidiospores bud off in a basipetal manner from the terminal portion of the basidium. The 
spores are initially unencapsulated but quickly develop capsule and begin budding as 
yeasts thus completing the sexual cycle. C.neoformans contains only one MAT locus and 
it occurs in 2 idiomorphic forms corresponding to the two mating types a and α. It has 
been observed that environmental and clinical isolates are predominantly of α mating type 
occurring in 30-40 fold higher magnitudes than the corresponding a mating counterparts52. 
 Cryptococcus neoformans can undergo intra or inter varietal mating (serotype A x 
A, A x D, D x D) and the resulting teleomorph is called Filobasidiella neoformans var. 
neoformans. Mating in C.gattii (B x B, B x C, C x C) produces the teleomorph 
Filobasidiella neoformans var. bacillispora. The teleomorph of the two species can be 
distinguished on the basis of morphology51. Filobasidiella neoformans var. neoformans 
produces chains of spherical basidiospores whereas Filobasidiella neoformans var. 
bacillispora produces chains of oval/elliptical basidiospores. Cryptococcus can also 
undergo interspecies matings (B x D, A x C, C x D) but the viability of the basidiospores 
is reduced and many aneuploid progeny are generated indicating that genomic divergence 
impairs meiosis58.  
 The mating of Cryptococcus neoformans has been observed in the laboratory under 
certain conditions like room temperature, minimal water exposure and environmental 
pCO2 concentrations. Non enriched media such as V8 juice agar, hay infusion agar or bird 
guano filtrate agar are suitable for mating of C.neoformans in the laboratory. 
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 Cryptococcus neoformans var. neoformans strains undergo monokaryotic fruiting, 
a modified form of sexual reproduction occurring between strains of the same mating 
type52. During this process, cells of one mating type eg., α become diploid α / α , either by 
endoduplication or by nuclear fusion following cell fusion between two α cells. The 
diploid monokaryotic hyphae form rudimentary clamp connections. At the stage of 
basidium development, meiosis occurs and haploid basidiospores are produced in four 
chains. Monokaryotic fruiting is predominantly observed in α strains and this might 
explain why α strains are more abundant36. 
ECOLOGY 
Cryptococcus species are saprobes found in decaying wood, soil, fruits and 
vegetables73. It is now clear that C.neoformans and C.gattii reside in separate 
environmental niches. In 1955, Emmons first isolated C.neoformans from soil, pigeon 
droppings and pigeon nests26. The soils that most commonly yield C.neoformans are those 
which are frequented by pigeons, chickens, turkeys and to a lesser extent by canaries and 
parrots. Pigeons however seldom develop clinical disease due to Cryptococcus. This is 
explained by the fact that the average body temperature of pigeons is as high as 420C 
which allows survival in the gut but is not conducive to the growth of C.neoformans77. 
Since C.neoformans can metabolise creatinine which is abundant in bird guano, it is likely 
that there is a natural selection for C.neoformans to inhabit and grow in this niche. C.gattii 
unlike C. neoformans has never been cultivated from bird guano. The lack of C.gattii in 
the excrement of birds can be explained due to the high pH present in bird guano as 
C.gattii is more sensitive to pH changes than C.neoformans76. Ellis and Pfeiffer in 1990 
cultured C.gattii from vegetation around river red gum trees (Eucalyptus camaldulensis) 
and forest red gum trees (E.tereticornis) in Australia25, 79. In recent years C.gattii has also 
been isolated from other gum trees such as flooded gum (E.rudis), blakely’s red gum 
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(E.blakely), tallow wood (E.microcorys), turpentine gum tree (Syncarpia glomulifera) and 
pink shower tree (Cassia grandis). In Columbia, C.gattii isolates have been found in 
several new species of trees such as Terminalia catappa, Ficus soatensis, Croton 
bogotanus, Coussapoa spp, Cupressus lusitanica, Pinus radiata, and Acacia decurrens58. In 
India it is prevalent in Syzygium cumini trees18. In the 2002 outbreak of C.gattii on 
Vancouver Island, Canada, the fungus was recovered from alder, douglas fir, garry oak, 
arbutus and cedar trees90. These indicate that C.gattii is associated with panoply of 
potential host trees.      
EPIDEMIOLOGY 
 Cryptococcus neoformans is prevalent worldwide with different geographic 
regions showing some differences in the strain prevalence. Serotype A is overwhelmingly 
prevalent over all other serotypes. Serotype D is generally restricted to European countries 
especially Denmark, France, Germany, Italy and Switzerland 75. In a review of 725 clinical 
isolates of Cryptococcus by Kwon- Chung and Bennett 8, 80% of all isolates were 
C.neoformans and of these isolates 80% were C.neoformans var. grubii.  
Majority of patients with disseminated cryptococcosis have an underlying 
immunocompromised condition. However, upto 20% of patients may not have any 
apparent underlying disease or risk factor (Pappas et al 2001)77.  
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CONDITIONS ASSOCIATED WITH PREDISPOSITION TO CRYPTOCOCCUS 
NEOFORMANS INFECTION 
HIV infection 
Lymphoproliferative disorders 
Haematological malignancies (CLL) 
Hyper IgM syndrome 
Treatment with monoclonal antibodies 
(Infliximab) 
Systemic Lupus Erythematosus 
Organ transplantation 
Sarcoidosis 
Corticosteroid therapy 
Idiopathic CD4 Tcell lymphopenia 
Peritoneal dialysis 
Cirrhosis 
 
The incidence of cryptococcal infection peaked with the spread of the AIDS 
pandemic. Following widespread use of HAART, the incidence has shown a declining 
trend 3. But still Cryptococcus continues to top the list of culture proven cases of 
meningitis in areas of the world with less access to ART. 
            The medical fraternity witnessed a rise in cryptococcal infections in solid organ 
transplant (SOT) recipients as a result of prolonged immunosuppression. In one study, 
cryptococcosis occurred in 2.8% of all infections encountered in SOT recipients75. The 
risk is greater for renal and liver transplant recipients when compared to bone marrow 
transplant recipients. 
Increased use of corticosteroids has also contributed to the rise in the number of 
cryptococcal infections. Most of the affected patients in this cohort are infected with 
C.neoformans var. neoformans (serotype D).77 
            Cryptococcus gattii was generally considered to be restricted to tropical and 
subtropical areas such as Australia, Brazil, Central Africa, Hawaii, Southern California 
and South East Asia corresponding to the distribution of its ecological niche. However, an 
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outbreak of C.gattii on Vancouver Island has unraveled that the yeast is actually more 
widespread than was actually thought of. 7, 90 More than 160 human cases caused mainly 
by VGII genotype were reported and 6 proved to be fatal. Over the decades, C.gattii has 
been associated with infections in immunocompetent hosts and only rarely affects patients 
with AIDS. The reason why AIDS patients are less likely to develop C.gattii is not known. 
It has been hypothesized that since HIV is predominantly an urban infection, these patients 
may not be exposed to the ecological niches of C.gattii. It is also likely that C.neoformans 
produces dormant infections which are reactivated during HIV infection in contrast to 
C.gattii which may produce disease during the primary infection itself 77. Of late, C.gattii 
is emerging as a pathogen even in immunocompromised hosts. It has been reported to 
cause 10% of cryptococcal infections in AIDS patients in Southern California and in 
Botswana and Malawi in Sub- Saharan Africa 58. In India too, there are few recent reports 
stating the isolation of C.gattii from HIV patients 14, 71. 
Cryptococcosis is predominantly a disease of adults with males being more 
commonly affected than females76. Children, however seldom seem to be affected by this 
yeast including those with AIDS1, 76. The explanation for the rarity of the disease in 
children still remains an enigma despite studies showing that most children acquire 
antibodies to Cryptococcus before the age of 10 (Chen et al 1999, Goldman et al 2001)32. 
It is interesting to note that several children with Hyper IgM syndrome tend to develop 
cryptococcal infections75. The exact mechanisms underlying this association need to be 
elucidated further.  
Human to human transmission of Cryptococcus does not occur except in cases of 
transplantation of infected tissue 9(Beyt & Waltman 1978, Kanj et al 1996).  
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Although a wide range of animals and avians are infected by cryptococcal species, 
cryptococcosis has not been generally reported as a zoonosis. In 2000, Nosanchuk et al 
reported a single case of C.neoformans infection in a transplant recipient whose strain was 
identical to the one isolated from the cage of his pet cockatoo72. Except for this isolated 
report, there has been no documentation of such related transmissions so far. Cryptococcus 
affects both domestic and wild animals and the clinical presentation often differs from that 
in humans58. Cryptococcosis in cats presents mostly as upper respiratory tract infection. 
Dogs commonly develop severe disseminated disease with CNS and ocular involvement. 
Cryptococcal infection leads to mastitis and pneumonia in herds of cattle or goats. In 
horses, obstructive growths are seen in the nasal cavity and in koalas, asymptomatic nasal 
or skin colonization occurs. Despite the well known association of C.neoformans with 
pigeons for over 50 years, clinical disease is seldom encountered and they most probably 
serve as vectors in dissemination of the yeast10.  
PATHOGENESIS 
Human infection is acquired primarily by inhalation of Cryptococcus into the lung 
alveoli. It is still unclear whether basidiospores or yeast cells are the infectious propagule 
of C.neoformans58. The ciliary action of respiratory epithelium removes particles >5µ, 
such as encapsulated yeast cells. Basidiospores, which are <2µ can ideally get lodged in 
the lung alveoli. However, yeast cells can get reduced to a size of 3µ or less by losing the 
capsule under conditions of nutrient deprivation and low moisture. But, basidiospores are 
more resistant than encapsulated yeast cells to dessication and readily become airborne 
and hence could more likely be the initiators of pulmonary infection. However, more 
studies are needed to confirm these hypotheses.  
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The ultimate presentation of cryptococcosis is a reflection of the complex 
interactions between the virulence of the infecting strain and host defence mechanisms. 
Once infection is established, one of the three possible processes could take place- 
1. In an immunocompromised host, the yeast continues to proliferate and 
disseminate, causing clinical disease 
2. In an immunocompetent host, effective immune response completely eliminates 
the yeast from the host 
3. The yeasts produce a small lung/lymph node complex and remain dormant in 
tissues  
The most important determinants of virulence in Cryptococcus include possession 
of a capsule, production of melanin and growth at 370C.  
Capsule- The polysaccharide capsule is a major virulence factor for C.neoformans 
composed of unbranched chain of α-1, 3 linked mannose units substituted with xylosyl and 
β glucuronyl groups. About 80% of the capsule is made of glucuronoxylomannan while 
galactoxylomannan accounts for the remaining 20% 77.The serotypes of C.neoformans 
differ in the degree of mannosyl substitution, in the molar ratios of mannose, xylose and 
glucuronic acid and in the percentage of O-acetyl attachments. Mutant cryptococci that are 
hypocapsular or acapsular are less virulent in animal models than encapsulated strains31. 
Similarly, infection caused by poorly encapsulated strains is associated with less severe 
disease. The size of the capsule varies between strains and can account for >50% of the 
yeast diameter in some strains. Several physiological conditions like ambient pCO2, 
presence of serum and limited availability of ferric ions increase the capsular size 
(Granger et al1985; Vartivarian et al 1993; Zargoza et al 2003). The capsular material can 
be shed from the yeast into body fluids such as blood and CSF. The capsular 
polysaccharide has the following effects on immunity: antiphagocytosis, decreases 
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antibody responsiveness, depletion of complement, inhibition of leucocyte migration, 
dysregulation of cytokine secretion77. Signaling pathways employing cAMP control the 
expression of capsule production and down regulation of this pathway produces an 
attenuated virulence phenotype. 
Melanin production- C.neoformans and C.gattii are unique among other members 
of the genus in possessing a laccase. The enzyme laccase (phenol oxidase) catalyses the 
conversion of diphenolic compounds such as L- dopa, nor-epinephrine and epinephrine to 
quinones which rapidly autopolymerise to form melanin75. The gene encoding for laccase 
is present on the inner aspect of the cytoplasmic membrane of the yeast and laccase 
negative, albino mutants exhibit attenuated virulence in animal models53. The propensity 
of Cryptococcus to invade the CNS may partially be explained by its ability to degrade 
naturally occurring catecholamines to an antioxidant protecting the yeast when it is in the 
catecholamine rich CNS77. Other postulated reasons for the neurotropism include the 
probable presence of specific receptors on neuronal cells coupled with availability of 
nitrogen sources like asparagine and creatinine in the CSF84. Melanin accumulates in the 
cell wall and provides support to the cell wall, interferes with T cell responses and also 
protection from temperature changes and antifungal agents.  
 Growth at 370C- The pathogenic cryptococci like other pathogenic fungi grow 
well at 370C. Calcineurin and RAS signaling pathways are associated with the yeast’s 
ability to grow at mammalian body temperatures 2(Alspaugh et al 2000). Presence of a 
vacuolar ATPase and the stress sugar, trehalose also enable the yeast to withstand host 
body temperature. Mutants of C.neoformans that cannot grow well at this temperature are 
less virulent even when they possess capsule and laccase activity (Kwon- Chung et al 
1982). Higher body temperatures nearing 400C slow the growth rate of the strains with 
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production of aberrant budding patterns and pseudohyphal forms. Isolates of serotype B, C 
and D are more sensitive to growth inhibition at higher temperatures than serotype A64.  
Other factors linked to virulence include possession of phospholipase and urease 
enzymes, genes for superoxide dismutase, production of mannitol and mating strain α75. 
Mutants of phospholipase B gene (PLB1) are hypovirulent; so are mutants with loss of the 
gene for urease enzyme, URE1. Mannitol scavenges free radicals that may damage the 
yeast and also contributes to the formation of brain edema. Α study by Neilson et al 
showed that α strains of C.neoformans are more virulent than congenic a strains and these 
α strains are also more likely to penetrate the CNS during co- infection with congenic a 
strains. 
IMMUNOLOGY 
The earliest innate immune response to the entry of infectious propagules of 
Cryptococcus in the lung is mediated by alveolar macrophages. Most primary infections of 
the lung are asymptomatic in immunocompromised individuals because they are readily 
contained by the immune system. Patients with intact immunity mount a Th1 cytokine (IL-
2, INFγ, TNFα) response culminating in a granulomatous type of inflammatory lesion. 
Several studies have emphasized the role of CD4 and CD8 cells in containing the 
dissemination of cryptococci from the lungs to the CNS. The cause for neurotropism of 
Cryptococcus is not very clear but might also be related to the lack of inhibitory action of 
serum and that the CNS may provide a refuge for Cryptococcus from host immune 
responses84. The lack of an effective CMI in patients with AIDS culminates in rapid 
dissemination of yeast cells throughout the body and a relatively higher fungal burden in 
tissues when compared with immunocompetent patients. It has been observed that patients 
infected with C.gattii usually present with cranial nerve palsies and hydrocephalus. The 
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likely explanation is that these strains being less virulent might permit a robust immune 
response which results in an insidious presentation and focal neurological signs.   
Disseminated cryptococcosis in the immunocompromised host may be due to reactivation 
of latent infection or sometimes, a primary uncontained infection due to an ineffective 
immune system. The concept of reactivation of a dormant focus of cryptococcal infection 
is strengthened by studies in France showing that African ex-patriots who lived in Europe 
for many years prior to the development of disease possessed an infecting strain consistent 
with the genotype found in African strains75.  
Since cryptococcosis is a rare event despite the fact that cryptococci are 
widespread in the environment, it is likely that most primary infections in the general 
population are sub-clinical. Due to the immunologically inert nature of the polysaccharide 
capsule of Cryptococcus, little antibody response is elicited following infection and no 
satisfactory skin test has been developed so far. With increasing studies pointing to the 
role of humoral immunity in recovery from cryptococcosis, focus on this arena has started 
gaining a foothold. With encouraging results of formation of high antibody titres to 
Cryptococcus in mice immunized with a Polysaccharide- Tetanus Toxoid conjugate 
vaccine, the hope for a human vaccine has been elevated77. These antibodies may facilitate 
opsonisation and enhance the functions of Natural Killer cells. Besides, some studies have 
also shown that antibodies to glucosyl ceramide and melanin are targets of humoral 
immunity in addition to the capsule74.                  
CLINICAL MANIFESTATIONS 
Although the lung and CNS are the most common sites of infection, Cryptococcus 
can virtually disseminate and infect any organ of the human body85. Multiple site 
involvement is often noticed in the severely immunocompromised host. 
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Pulmonary cryptococcosis- The presentation of pulmonary cryptococcosis may 
vary from asymptomatic colonization to life threatening pneumonia with evidence of 
Acute Respiratory Distress Syndrome (ARDS) 46. Moreover, patients with AIDS may also 
be co-infected with other pathogens like Mycobacteria, Nocardia, Pneumocystis or 
Histoplasma further complicating the clinical diagnosis. Symptomatic patients present 
with fever, chest pain, cough with expectoration of mucoid sputum and rarely 
haemoptysis. Immunocompromised hosts often present with a meningeal rather than 
pulmonary syndrome due to rapid dissemination of the yeast to the CNS. Hence, it has 
been postulated that isolation of Cryptococcus from the lung of a patient with high risk for 
dissemination must be followed by a lumbar puncture to rule out CNS infection even in 
the absence of symptoms 75. It has been estimated that about 90% of AIDS patients with 
cryptococcal pneumonia present with concomitant CNS infection at the time of initial 
diagnosis76.  
CNS cryptococcosis- Cryptococcal involvement of the CNS often manifests in the 
form of subacute meningitis or meningoencephalitis albeit acute and chronic meningitis 
may occur. Patients generally present with headache, fever, lethargy, altered sensorium of 
few weeks duration85. Patients with C.gattii infection have a higher tendency to develop 
cryptococcomas and may present with signs of raised intracranial tension (ICT) like 
vomiting, cranial nerve palsies or hemiplegia76. Obstructive hydrocephalus ensues in some 
patients and can result in personality changes or dementia. Rarely, severely 
immunocompromised patients with cryptococcal meningitis can present with rapidly 
developing coma and death.  
Cutaneous and mucocutaneous cryptococcosis- With rare exceptional cases, 
skin lesions in cryptococcosis herald an underlying disseminated infection and occur in 
about 10-15% of cases22. Direct inoculation of Cryptococcus into the skin following 
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trauma or laboratory accidents has also been reported76. C.neoformans can produce almost 
any type of skin lesion ranging from papules, plaques and vesicles to ulcers and draining 
sinuses87. Most of the lesions tend to involve the face, neck or the scalp. Some of the 
lesions might be mistaken for molluscum contagiosum, herpes or rarely carcinoma/ 
kaposi’s sarcoma. In patients who are profoundly immunocompromised, skin lesions may 
take the form of an abscess or rapidly progressing cellulitis. Akin to the occurrence of co-
infection at other sites, cutaneous cryptococcosis may be associated with other 
disseminated fungal infections of the skin. Hence, biopsy with proper histopathology and 
culture is essential to arrive at a correct diagnosis. Patients infected with serotype D strains 
of C.neoformans tend to have a higher rate of skin involvement than those infected with 
serotype A strains. Singh et al in 1997 observed that solid organ transplant recipients on 
tacrolimus therapy for immunosuppression had a higher ratio of skin and soft tissue 
infection relative to CNS infection89. This has been attributed to the anticryptococcal 
activity of tacrolimus at 37-390C but not at lower temperatures enabling the yeast to 
multiply in the skin. Mucocutaneous lesions are rarer when compared with skin lesions 
and present as nodules, granulomas or ulcers.   
Osseous cryptococcosis- Bone is involved in upto 5% of disseminated cases of 
cryptococcosis. Cranial bones, vertebrae and bony prominences are often involved with a 
contiguous soft tissue abscess. Patients generally present with pain and swelling of the 
affected area for a long period.  
Visceral cryptococcosis- In disseminated cryptococcosis any organ of the body 
may have foci of infection. Most commonly, the infection takes the form of granulomatous 
lesions which may be mistaken for neoplasia84. 
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Ocular cryptococcosis is a relatively common event in patients with disseminated 
cryptococcosis. There are also anecdotal reports of eye being the portal of entry of 
Cryptococcus following traumatic inoculation9 (Beyt & Waltman 1978, Granger et al 
1986, Birkmann & Bennett 1988). The most common ocular manifestations are palsies 
and papilledema. Optic neuritis or endophthalmitis can result in severe visual loss. In some 
cases, compression of the ophthalmic artery secondary to raised ICT is responsible for loss 
of vision. 
            Infection of the prostate gland is yet again common in dissemination 
cryptococcosis and the prostate may serve to protect the yeast during antifungal therapy57. 
            In rare instances, Cryptococcus may cause endocarditis, mycotic aneurysms, 
peritonitis, renal abscess, adrenal insufficiency, hepatitis, thyroiditis, breast abscess or 
genital ulcers76.  
LABORATORY IDENTIFICATION 
A) MICROBIOLOGICAL TECHNIQUES: 
Although CSF in CM is usually clear and can be viewed directly under the 
microscope, sputum and pus samples must be digested in 10% KOH mount before 
performing a microscopic examination. 
WET MOUNTS- The yeasts of C.neoformans are quite fragile and collapse in 
dried, fixed or stained films. Hence wet preparations are ideal for rapid identification of 
Cryptococcus in the laboratory. When the infected material containing cryptococci is 
mixed with a drop of India ink, 10% Nigrosin or other colloidal mounting medium, the 
encapsulated yeast cells of Cryptococcus (5-10µ) are delineated by negative contrast. 
Some amount of expertise is needed to differentiate the yeast cells from WBCs, RBCs or 
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talc granules that may have dropped from the gloves while preparation of the mount. The 
sensitivity of an India ink preparation is usually >75% in AIDS patients and only upto 
50% in non- HIV infected patients with cryptococcal meningitis54. Usually, a 
concentration of yeast >104 CFU /ml of CSF is necessary for detection by India ink 
preparation. A modified India ink preparation using 2% mercurochrome (Rito Zerpa et al, 
1996) allows identification of external and internal structures of Cryptococcus with clear 
distinguishing of 3 layers of the capsule 96. Internal corpuscles corresponding to different 
sizes of endogenous spores of the yeast are visible clearly in the modified preparation. 3 
layers of the cryptococcal capsule namely lucent stratum, fibrillar material and light zone 
are easily made out in these preparations which are otherwise discerned only under the 
electron microscope.    
GRAM STAIN- A Gram stain performed on sediment from a cytospin preparation 
of CSF shows the presence of pus cells and gram positive budding yeast cells. 
CALCOFLUOR WHITE (CFW) STAIN- Can be used to identify Cryptococcus 
in cases where the number of yeast cells is expected to be scanty. 
CULTURE- CSF sample must be inoculated on Sabouraud Dextrose Agar (SDA) 
with antibiotics but without cycloheximide as it inhibits the growth of Cryptococcus. 
Cultures must be incubated at 370C and 250C for a period of 4 weeks before declaring as 
sterile27. The yield of a positive culture is increased by culturing large volumes of CSF 
(10-12ml). Yeast like, mucoid, cream to buff coloured colonies of Cryptococcus generally 
appear after 2-3 days but may be delayed for over a week in case of patients on antifungal 
therapy. Rare, acapsular variants may produce dry or glabrous colonies84. An LCB mount 
from the colonies would show the presence of budding yeast cells. A negative culture does 
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not rule out cryptococcosis since the CSF is sterile in cases of cryptococcomas or in 
instances where very few organisms might have been present in the CSF.  
GROWTH ON SPECIAL MEDIA: 
1. CORN MEAL AGAR- Cryptococcus grows as yeast cells that exhibit narrow based 
budding without production of pseudohyphae. 
2. STAIB’S  AGAR- On Staib’s agar containing extract of niger seed (Guizotia 
abyssinica), C.neoformans and C.gattii produce brown coloured, mucoid colonies by 
production of melanin from the substrates using the enzyme, phenol oxidase16. Other 
media employing the same principle are Pal’s sunflower seed agar (containing 
Helianthus annuus) and a synthetic medium made of caffeic acid containing ferric 
citrate. Nardelli et al (2004) developed a Minimal Synthetic Caffeic Acid Medium 
(MSCAM) containing only caffeic acid, ferric citrate and noble agar without 
glucose, vitamins or mono/bivalent ions. They observed rapid pigment production 
and concluded that absence of glucose or Ca++ or NH4+ does not interfere with the 
activity of phenol oxidase. Vanessa et al (2005) modified Staib’s medium without 
creatinine and observed rapid production of intensely pigmented brown colonies by 
C.neoformans. 
3. CANAVANINE- GLYCINE- BROMOTHYMOL BLUE (CGB) AGAR- CGB 
medium is used to differentiate C.neoformans from C.gattii. The latter is resistant to 
the action of L-canavanine and can utilize glycine as the sole source of nitrogen 
producing a cobalt blue colour change16. Glycine Cycloheximide Phenol red agar 
(GCP) is also based on the principle of ability of C.gattii to utilize glycine.  
4. CREATININE- DEXTROSE- BROMOTHYMOL BLUE- THYMINE (CDBT) 
AGAR- Used to differentiate C.neoformans var. grubii and var. neoformans. The 
latter will assimilate thymine and grow as red coloured colonies on this medium38. 
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BIOCHEMICAL TESTS: 
1. UREASE TEST- Members of the genus Cryptococcus have the ability to hydrolyse 
urea which could be detected on Christensen’s urease medium or even within 10-
30mts using a rapid urea broth. Using a modified urease assay, Kwon- Chung in 
1987 demonstrated that the urease activity of C.gattii is suppressed following 
chelation with 100µM EDTA while that of C.neoformans is not77. Robert et al 
used 1% benzalkonium chloride with urea agar base for presumptive identification 
of Cryptococcus within 10-15 minutes97. 
2. NITRATE REDUCTION- C.albidus and C.terreus can reduce nitrate to nitrite. 
3. NITRATE ASSIMILATION- C.laurentii is the species of Cryptococcus that 
assimilates nitrogen. 
4. ASSIMILATION OF AMINO ACIDS- Used to differentiate C.neoformans from 
C.gattii as the latter can use D- proline24 or D- tryptophan as the sole source of 
nitrogen. 
5. ASSIMILATION OF CARBOHYDRATES- All cryptococci are non-fermentative 
and vary in their ability to assimilate carbohydrates77, 84. 
Cryptococcal 
species 
Carbon assimilation 
Inositol Dextrose Lactose Maltose Melibiose Sucrose 
C.neoformans 
and its var. 
 
+ 
 
+ 
 
- 
 
+ 
 
- 
 
+ 
C. albidus 
and its var. 
 
+ 
 
+/w 
 
+/- 
 
+ 
 
+/v 
 
+ 
C.laurentii 
and its var. 
 
+ 
 
+ 
 
+ 
 
+ 
 
+/- 
 
+ 
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C. luteolus 
 
+ 
 
+ 
 
-/w 
 
+ 
 
+/w 
 
+ 
 
C.melibiosum 
 
+ 
 
+ 
 
w 
 
- 
 
+ 
 
- 
 
C.terreus 
 
+ 
 
+ 
 
+/w 
 
V 
 
- 
 
- 
 
Note: + denotes sugar is assimilated, - denotes sugar is not assimilated, v- variable,       
w- weak assimilation of sugar 
IMMUNODIAGNOSIS- The polysaccharide antigen of cryptococcal capsule is 
shed from the surface of the yeast cells and may be detected in serum, CSF, urine or rarely 
BAL94. The test is performed using commercially available Latex agglutination kits (LAT) 
or more recently by Lateral flow assays (LFA) employing immunochromatographic 
principles53. These tests are highly sensitive and can detect even 10ng/ml of the 
polysaccharide in the specimen. A cryptococcal antigen titre > 1:8 is generally regarded as 
significant. The titre is highest in serum followed by CSF and urine75. False positive 
results may occur in upto 15% of the cases especially at titres <1:32. These might be due 
to the presence of rheumatoid factor in serum or in cases of infections with organisms that 
share cross reacting antigens like Trichosporon, Capnocytophaga or Stomatococcus and 
can be eliminated by pre-treatment of the serum with pronase or 2- mercaptoethanol76. 
False negative results on the other hand may result from prozone effect especially in 
serum samples and may be overcome by diluting the sample. Sujatha et al (2003) 
compared commercially available LAT with in- house Co-Agglutination (Co-A) test in 
150 cases of chronic meningitis for detection of cryptococcal antigen in CSF. They 
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reported that Co-A test is inexpensive and useful adjuvant to microscopy and culture in 
diagnosing CM.  
Detection of antibodies to Cryptococcus may be performed using agglutination, 
indirect fluorescent antibody test, complement fixation tests or EIA. However, these are 
not very reliable due to frequent occurrence of cross reactions with other diseases. 
            Serotyping techniques used in the past employed slide agglutination techniques 
using eight factors or five factors sera prepared by adsorption of rabbit polyclonal 
antisera75. These are unique to a particular serotype (factor 5- serotype B, factor 6- 
serotype C, factor 7- serotype A, factor 8- serotype D) or shared by two or more serotypes 
( factor 1- A, B, C, D; factor 2- A, B, D; factor 3- A, D; factor 4- B, C). A positive 
agglutination titre is generally 1:8 and above. Similarly, dot immune assays with serotype 
specific antisera were also in vogue. In addition, commercially available EIAs employing 
monoclonal antibodies can also differentiate the serotypes. 
MOLECULAR METHODS- The species and serovar of cryptococcal strains may 
be determined by PCR fingerprinting using (GACA) 4, (CAC) 5 and FM1 primers. Species 
specific DNA probes using ribosomal ITS sequences have also been developed58. In 
Restricted Fragment Length Polymorphism (RFLP) analysis, C.neoformans repetitive 
element 1 (CNRE-1) hybridizes effectively with DNA of serotype A yielding 11-16 bands 
while 5-11bands are obtained with serotype D due to poor hybridization66. Multi Locus 
Enzyme Electrophoresis (MLEE) also produces serotype specific patterns such as ET1-4 
(A), ET8-12 (D) and ET13-19 (B &C). Electrophoretic karyotyping by contour- clamped 
homogenous electrophoresis relies on the differences in the size and number of 
chromosomes of Cryptococcus. The number varies from 12.8 in C.neoformans var. 
neoformans to 13 for C.gattii and 121 for C.neoformans var. grubii. Random 
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Amplification of Polymorphic DNA (RAPD) analysis using mini-satellite specific core 
sequence of the wild type phage M13 (5’GAGGGTGGCGGTTCT3’) as a single primer 
followed by amplification effectively identifies the genotypes of Cryptococcus. The 
mating type of C.neoformans can be determined using MLST techniques58. 
IN- VITRO ANTIFUNGAL SUSCEPTIBILITY TESTING- The reference 
broth dilution method recommended by Clinical and Laboratory Standards Institute 
(CLSI) is ideal for determining the MIC of antifungal agents to Cryptococcus20. The 
methodology has been standardized for media, inoculum and end point determination to 
test antifungal agents against Cryptococcus spp. However, E test may also be used to 
determine the MIC of antifungal agents to Cryptococcus. Commercially available 
automated systems like Vitek-2 can also be used for identification as well as MIC 
determination of Cryptococcus. 
B) OTHER ANCILLARY TESTS: 
1. BIOCHEMICAL EXAMINATION OF CSF- WBC cell count is generally 
elevated with mononuclear cell predominance (>50/µl) but may be low in patients 
with AIDS54. Glucose levels are slightly reduced and a modest rise in the level of 
proteins is observed. However, all parameters may be normal in severely 
immunocompromised patients76. 
 
2. HISTOPATHOLOGICAL EXAMINATION OF BIOPSY SPECIMENS- 
Presence of budding yeast cells in tissues surrounded by empty spaces can be 
observed using Periodic Acid Schiff (PAS), Haematoxylin and Eosin (H&E) or 
Gomori Methenamine Silver (GMS) stains. Rarely, aberrant mycelial forms may also 
be observed. Detection of the capsule using Alcian blue or Meyer’s Mucicarmine is 
very helpful in the diagnosis by staining it blue or pink respectively75. For rare, 
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acapsular variants, Masson- Fontana stain must be employed to demonstrate the 
production of melanin by the yeast76. 
 
3. RADIOLOGY- Varied lesions may be present in chest roentgenogram of patients 
with pulmonary cryptococcosis including nodules, local/diffuse infiltrates, hilar 
lymphadenopathy and rarely, cavitation or pleural effusion46. 
Patients with cryptococcal meningoencephalitis can have normal CT and MRI scans 
on imaging. However, CT may reveal single/multiple nodules suggestive of 
cryptococcomas and also presence of hydrocephalus. MRI scans too may show 
hyperintense clustered foci on T2WI and non-enhancing on postcontrast T1WI in the basal 
ganglia or midbrain75.  
X-ray in osteomyelitis caused by Cryptococcus generally reveals one or more, well 
circumscribed osteolytic lesions and the absence of periosteal proliferation is indicative 
of cryptococcosis rather than other mycoses84.    
 
4. ANIMAL PATHOGENICITY TESTING- Suspected clinical specimen or a 
suspension of young culture is inoculated into swiss albino mice. The animals 
generally die in 7-10 days and yeast cells can be demonstrated in various visceral 
organs and body fluids76. 
MANAGEMENT 
Cryptococcal meningitis is almost uniformly fatal unless appropriate antifungal 
therapy is instituted. Based on data analysed from several large scale studies, the current 
WHO recommendations for treatment of an episode of CM is a 2 phase approach- 
Induction followed by Consolidation82 
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Induction phase- Amphotericin B deoxycholate is administered at a dose of 
0.7mg/kg/day in combination with flucytosine 100mg/kg/day for a period of 2 weeks. 
Liposomal amphotericin B 4mg/kg/day may also be used with reduced toxicity. 
Consolidation phase- Fluconazole is administered at a dose for 400-800mg/day for 
8 weeks 
Suppressive prophylaxis- Tab. fluconazole is administered daily at a dose of 
200mg/day. Discontinuation of anti-fungal maintenance treatment is recommended based 
on the following criteria82 
 
a. If HIV viral load monitoring is not available  
When patients are stable and adherent to ART and anti-fungal maintenance 
treatment for at least one year and have a CD4 cell count of greater than or equal to 200 
cells/µl (two measurements six months apart).  
 
b. If HIV viral load monitoring is available 
Patient is stable and adherent to ART and anti-fungal maintenance treatment for at 
least one year and with a CD4 cell count of greater than or equal to 100 cells/ µl (two 
measurements six months apart) and a suppressed viral load. 
Maintenance treatment for cryptococcal disease should be restarted if CD4 count 
drops to <100 cells/ µl or if a WHO stage 4 clinical event occurs 
            Relapse in a case of cryptococcal meningitis is defined when an episode of CM 
occurs with the following characteristics40- (1) previous laboratory confirmed case of 
cryptococcal meningitis (2) recurrence of symptoms of meningitis (3) CSF India ink, 
antigen test (CRAG) and/or culture positive for Cryptococcus at this presentation (4) no 
alternative diagnosis. These relapse episodes can occur in patients who fail to take 
secondary fluconazole prophylaxis or even in patients on fluconazole prophylaxis before 
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the institution of HAART. A patient can present with more than one episode of relapse if 
there is resolution of symptoms and atleast one month between episodes. Sometimes, a 
relapse episode could be due to Immune Reconstitution Inflammatory Syndrome (IRIS) 40.  
It is defined as (1) microbiologically confirmed first episode of CM (2) resolution of CM 
symptoms before starting ART (3) self-reported adherence to fluconazole and ART (4) 
recurrence of symptoms of meningitis after initiation of ART (5) no alternative diagnosis, 
including fluconazole resistance, found on laboratory testing and clinical review. 
Immediate ART initiation is not recommended in HIV-infected patients with cryptococcal 
meningitis due to the high risk of IRIS which may be life-threatening 69, 88. WHO 
guidelines state that ART initiation should be deferred until there is evidence of a 
sustained clinical response to anti-fungal therapy 82, and usually after 2-4 weeks of 
induction and consolidation treatment with amphotericin B combined with flucytosine or 
fluconazole. 43  
 
Supportive measures- In patients with very high intracranial pressures, repeated 
lumbar punctures with a wide bore needle may be needed33, 60. Additionally, optic nerve 
fenestrations might be required to prevent visual loss due to the effects of raised ICT. A 
ventriculo-peritoneal shunt procedure is often necessary in patients with non-
communicating hydrocephalus. Surgery for cryptococcomas especially those >3cm needs 
to be individualized on patient basis after administering adequate antifungal therapy75. 
Finally, the role of cytokines in accentuating the killing of cryptococci has been evaluated 
in few prospective human trials. Treatment with INF-γ had a remarkable reduction in yeast 
counts in the CSF but had little impact on the final outcome of the patients. More research 
needs to be done on the use of immunomodulators in the management of cryptococcosis58.                   
 
30 
 
PROGNOSTIC FACTORS 
The nature of the underlying illness of the patient is the most important 
determinant of the response to anticryptococcal therapy. Patients with advanced neoplasia 
or AIDS generally have a poor prognosis. Several studies have implicated that mortality 
rates are higher in patients with cryptococcal meningitis who exhibit the following 
features23, 62, 98 
1. High opening pressure on lumbar puncture (>250mm of H20) 
2. Higher yeast burden at the time of presentation as detected by India ink or elevated 
capsular polysaccharide antigen titre >1:1024 
3. Poor inflammatory response indicated by the paucity of WBCs in the CSF < 
20/mm3 
Further, the presence of headache is considered as a good prognostic factor as the 
patient generally seeks early diagnosis and treatment77. On the contrary, altered mental 
status or stupor is indicative of poor prognosis. 
PREVENTION 
 The use of prophylactic fluconazole therapy for preventing opportunistic fungal 
infections in AIDS patients with low CD4 counts has resulted in measurable decline in the 
incidence of cryptococcosis. In the pre- HAART era, 50-60% of patients relapsed after 
therapy was stopped but relapse rate reduced to 5% after introduction of suppressive 
therapy13. However, the threat of development of drug resistance remains a major concern. 
 In 1991, a GXM-TT conjugate vaccine was found to be protective in mice but 
human studies in patients with risk for cryptococcal infection are still lacking77. Few 
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reports also point to the role of serotherapy using poly or monoclonal antibodies but 
further studies are needed to define their clinical effectiveness.  
 High risk patients may also be refrained from entering sites with abundant 
aerosolized pigeon droppings as a measure to prevent infection. 
  
  
 
Materials and methods 
  
32 
 
MATERIALS AND METHODS 
 ETHICAL CONSIDERATION- Approval by the Institutional Ethics Committee, 
Madras Medical College and Institutional Review Board, Government Hospital of 
Thoracic Medicine was obtained prior to the commencement of the study. All patients 
satisfying the inclusion criteria were included in the study. Informed consent was obtained 
from the patients/ relatives (in case of patients with altered sensorium) and a structured 
questionnaire was used to obtain details of the patient. 
PLACE OF STUDY- The study was conducted on HIV positive patients admitted 
to the medicine wards of either of the two hospitals 
1- Rajiv Gandhi Government General Hospital, Chennai-3 
2- Government Hospital of Thoracic Medicine, Tambaram, Chennai- 47 
DURATION OF STUDY- The study was conducted over a period of one year 
between October 2011to September 2012 
INCLUSION CRITERIA- Patients infected with HIV and presenting with 
symptoms suggestive of meningitis like 
1. Fever  
2. Diffuse headache  
3. Nausea/vomiting   
4. Drowsiness/ altered sensorium 
5. Visual disturbances: blurring/ diplopia (or) photophobia  
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EXCLUSION CRITERIA- 
1. HIV negative patients presenting with features suggestive of meningitis 
COLLECTION OF SAMPLES- Under strict aseptic precautions, samples were 
collected from the patients and transported as soon as possible to the laboratory. 
Cerebrospinal fluid (CSF) and blood was collected from all patients included in the study. 
In addition; depending on the symptoms, sputum, touch smears of skin lesions, tissue 
biopsy or other samples were collected from patients presenting with extrameningeal 
involvement besides meningitis. 
COLLECTION OF CSF- Patient was placed in left lateral position. The spine 
was flexed and lumbar vertebrae L4 and L5 were identified. The skin was disinfected with 
70% alcohol and 10% povidone iodine. A spinal needle was introduced into L4-L5 
intervertebral disc space and about 3-5 ml of CSF was collected separately in three leak 
proof, sterile, screw capped containers- first one for biochemical analysis, next one for 
microbiological techniques and the last for cytology54. 
COLLECTION OF BLOOD SAMPLE- The venepuncture site was thoroughly 
disinfected with 70% alcohol for 30 seconds followed by betadine for 30 seconds to 1 
minute. The disinfection was done in circular movements in a unidirectional manner from 
the centre to periphery and 2ml of blood was collected in a vacutainer containing EDTA54.  
BIOSAFETY CONSIDERATIONS- In view of the infectious nature of the 
samples, all the procedures were carried out in a biosafety level 2 cabinets. Adequate 
protective equipments were used while performing the tests. The samples were disinfected 
in freshly prepared solution of 1% sodium hypochlorite for 30 minutes before disposal. 
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PROCESSING OF SAMPLES- CSF was centrifuged at 1500-2000 rpm for 10-
15 minutes and the deposit was used for performing India ink preparation, Gram stain and 
culture. The supernatant was used to perform LAT. In case of delay in processing, the CSF 
sample was incubated at 370C till further processing.  
INDIA INK PREPARATION- A loopful of centrifuged CSF sediment was 
placed on a clean glass slide and a drop of India ink was added to the slide. The sediment 
and India ink were mixed thoroughly with a sterile needle and a coverslip was carefully 
placed over the mixture avoiding air bubbles54. The preparation was viewed under 10X 
and 40X objectives of the microscope to look for presence of encapsulated, spherical, 
budding yeast cells. The edge of the coverslip was specifically examined as the yeast cells 
tend to move towards the periphery along with the fluid while placing the coverslip. In 
addition, the India ink was regularly checked for contamination by examining just the 
stain under the microscope.  
CSF samples with an ambiguous capsule were re-examined with a modified India 
ink preparation containing 2% mercurochrome96. A small drop of centrifuged CSF deposit 
was placed on a clean glass slide and a small drop of 2% mercurochrome was then mixed 
with the CSF on the slide. Then, a small amount of India ink was immediately added and a 
cover slip was placed without further mixing. The preparation was viewed under 10X and 
40X objectives of the microscope to appreciate the 3 layers of the capsule of cryptococcus. 
A clearly layered halo around the yeast cell against a pinkish-black background could be 
appreciated.  
GRAM STAIN- A clean glass slide was taken and a loopful of sediment placed on 
it to make a smear. The smear was air dried and fixed by flaming the slide. The smear was 
covered with methyl violet and left undisturbed for 1 minute. The slide was tilted to drain 
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the methyl violet and rinsed in flowing tap water. The smear was then covered with 
Gram’s iodine for 1 minute and rinsed in the same manner. Smear was decolourised with 
acetone for 1-2 seconds and quickly rinsed with water. The smear was finally covered with 
dilute carbol fuschin for 1minute and rinsed similarly54. The stained smear was air dried 
and observed under 100X oil immersion objective for the presence of gram positive, 
budding yeast cells. 
LATEX AGGLUTINATION TEST (LAT) - The supernatant from the 
centrifuged CSF sample was inactivated by placing in a boiling water bath for 5 minutes to 
reduce non-specific interference in the test. The kit used was Cryptococcal Antigen Latex 
Agglutination System (CALAS), [Meridian Biosciences]. The following procedure was 
followed- 
1. One drop of positive control was added to each of the two designated rings. 
2.  25 µl of the antibody control and negative control were added to the appropriate rings. 
3. 25 µl of CSF sample was added to each of the two designated rings. 
4. One drop of detection latex was added to each of the designated rings. 
5. Similarly, one drop of control latex was added to each of the designated rings.  
6. The contents of the rings were mixed using separate applicator sticks. 
7. The card was rotated at 125 rpm for 5 minutes on a rotator and the reaction was graded 
as follows: 
a) Negative: homogenous suspension of particles with no visible clumping 
b) 1+ : fine granulation against a milky background 
c) 2+: small but definite clumps against a slightly cloudy background 
d) 3+: large and small clumps against a clear background 
e) 4+ large clumps against a very clear background 
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 A reaction of 2+ or more with the detection latex was taken as positive for the 
presence of cryptococcal polysaccharide antigen in the CSF 
CULTURE- CSF sample was inoculated on two slants of Sabouraud Dextrose 
Agar (SDA) and incubated at 370C and 25°C respectively. The inoculated slants were 
inspected daily during the first week and twice weekly for another 3 weeks before 
discarding as negative27. 
Appearance of moist, mucoid, cream coloured colonies on SDA following 48-72 
hours of incubation was presumptively identified as Cryptococcus and further tests were 
done to confirm the identity of the isolate.  
GRAM STAIN: A Gram stain was performed on any yeast grown on SDA to 
ascertain the presence of gram positive, budding yeast cells. 
UREASE TEST: Detection of urease activity of Cryptococcus was performed 
using Christensen’s urease medium. Using a loop, a small amount of pure growth from a 
48-72hr old culture was inoculated on urease slants and the tubes were incubated at 25°C. 
If urease is present in the isolate, urea is split to ammonia which raises the pH turning the 
slant to deep pink colour due to the presence of phenol red indicator16. The urease test was 
declared negative only after 4 days. ATCC C.neoformans 32045 and ATCC C.albicans 
90028 were used as positive and negative controls respectively. 
GROWTH ON CAFFEIC ACID FERRIC CITRATE (CFA) MEDIUM: 2-3 
colonies of pure growth from a 48-72hr old culture were inoculated on CFA medium and 
the plates were incubated in dark at 25°C for upto 5 days. The appearance of dark brown 
colonies is interpreted as positive for melanin production29. ATCC C.neoformans 32045 
and ATCC C.albicans 90028 were used as positive and negative controls respectively. 
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GROWTH ON CANAVANINE- GLYCINE- BROMOTHYMOL BLUE 
(CGB) AGAR: 1-2 colonies of pure growth from a 48-72hr old culture were streaked on 
the surface of CGB slants using a straight wire loop and  incubated at 25°C for upto 5 
days. Development of a cobalt blue colour in the medium due to the rise in pH indicates 
that the isolate grown is C.gattii. The glycine in the medium is metabolised to ammonia by 
C.gattii which raises the pH to 7 from 5.8 changing the colour to blue16. An in-house 
C.gattii (serotype B) and ATCC C.neoformans 32045 were used as positive and negative 
controls respectively. 
GROWTH ON CREATININE- DEXTROSE- BROMOTHYMOL BLUE- 
THYMINE (CDBT) AGAR: 1-2 colonies of pure growth from a 48-72hr old culture 
were inoculated on CBDT medium and the plates were incubated at 25°C for upto 5 days. 
Growth of red colonies is indicative of assimilation of thymine by C.neoformans var. 
neoformans. C.neoformans var. grubii fails to grow on this medium due to its lack of 
ability to assimilate thymine38. ATCC C.neoformans 32045 (var. grubii) was used as 
negative control. 
ASSIMILATION OF CARBOHYDRATES- The pour plate auxanographic 
method of Wicherham and colleagues was used 28, 56. For testing each isolate, 90ml of agar 
(2%) was autoclaved at 1210C for 15 minutes. 0.67 grams of Yeast Nitrogen Base (YNB) 
was added to 5ml of distilled water and sterilized by filtration. Heavy yeast suspension 
made from 4-5 colonies of the 48-72 hr culture was added to 5ml of YNB prepared. It was 
emulsified to turbidity equal to 4 McFarland standard. The YNB & yeast suspension was 
added to 90ml of molten agar cooled at 45°C, gently swirled to distribute the yeast cells in 
the molten agar, and the entire volume was poured into a 150mm petri plate. Sugar discs 
were placed in a circle with sterile forceps, such that at least 30mm is present between 
centers of each disc and incubated at 25°C for 3-4 days. The discs used were inositol, 
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dextrose, cellobiose, lactose, maltose and sucrose. Appearance of growth around a sugar 
disc indicates assimilation of that sugar by the test isolate. Growth around dextrose disc 
was recorded first to signify the viability of the yeast. ATCC C.neoformans 32045 was 
used as control stain which assimilates dextrose, maltose and sucrose strongly. Inositol 
assimilation is delayed but positive while cellobiose is weakly assimilated. Lactose, 
however, is not assimilated. 
ASSIMILATION OF PROLINE- 11.7 grams of Yeast Carbon Base (YCB) was 
dissolved in 100ml of distilled water and sterilized by filtration. 20 grams of agar was 
dissolved in 980 ml of distilled water and dispensed as 18ml each in 18x 150mm screw 
capped test tubes and autoclaved at 1210C for 15 minutes. Yeast suspension was made by 
emulsifying 2-3 colonies of a 48-72 hr culture in 2ml of prepared YCB to obtain turbidity 
equal to 1 McFarland standard. The yeast suspension was added to 18ml of molten agar 
cooled at 45°C, gently swirled to distribute the yeast cells in the molten agar, and the 
entire volume was poured into a 90mm petri plate. A proline disc was placed with sterile 
forceps and incubated at 25°C for 7 days24. Presence of growth around the proline disc 
indicates assimilation of proline by the yeast. C.gattii assimilates proline while 
C.neoformans does not. Appropriate control strains were similarly tested. 
ANTIFUNGAL SUSCEPTIBILITY TESTING- Determination of Minimum 
Inhibitory Concentration (MIC) was done by microbroth dilution method as per CLSI 
M27-A3 protocol20. In addition, Epsilometer test was performed to compare its 
performance with the recommended microbroth dilution method.  
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MICROBROTH DILUTION METHOD:  
Amphotericin B powder was obtained from Himedia, Mumbai whereas 
voriconazole and fluconazole powders were obtained from Pharma Fabricon. Their 
potency was 750µg/mg each. 
Weight (mg) = volume (ml) x desired concentration (µg/ml)  
                                       Assay potency (µg/ml) 
Volume (ml) = weight (mg) x assay potency (µg/ml) 
                                       Concentration (µg/ml) 
STOCK SOLUTION:  
  For water soluble drugs like fluconazole sterile water was used as solvent, 
whereas for water insoluble drugs like amphotericin B and voriconazole, dimethyl 
sulfoxide (DMSO) was used. Stock solution of 5200µg/ml for fluconazole and 1600µg/ml 
for the other two drugs was prepared. The drugs were diluted from the stock solution in 
RPMI (fluconazole) or DMSO (amphotericin B and voriconazole) to obtain an 
intermediate solution. This was then further diluted 1:10 (fluconazole) or 1:100 
(amphotericin B and voriconazole) in RPMI to obtain the final strength. This procedure 
was done to avoid dilution artifacts that result from precipitation of compounds with low 
solubility in aqueous media. 
TEST MEDIUM USED:  
Rosewell Park Memorial Institute (RPMI) 1640 (with glutamine, without 
bicarbonate, phenol red as pH indicator) [Himedia, Mumbai] 
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INOCULUM PREPARATION: 
 All C.neoformans isolated from patients and ATCC C.neoformans were 
subcultured on Sabouraud Dextrose Agar and incubated at 35oC for 48hours to ensure 
purity and viability. The control strains, ATCC Candida krusei and ATCC C.parapsilosis 
were incubated for 24 hours only. Colonies were suspended in 5ml of sterile saline and 
adjusted to match turbidity of 0.5McFarland standard. The resulting yeast stock 
suspension of 1x106 - 5 x106 cells/ml was converted to working suspension by diluting it 
with RPMI 1640 broth medium in 1:100 followed by 1:20 dilution resulting in 5x102 - 
2.5x103 cells/ml.  
PROCEDURE 
Scheme for preparing dilution series of water soluble antifungal agents 
Antimicrobial solution 
Step  Concentration  
(µg/ml) 
Source  Volume  
(ml) 
RPMI 
Medium  
(ml) 
Intermediate 
concentration 
(µg/ml) 
Final concentration 
at 1:10  
(µg/ml) 
1         5120       stock 1 7 640      64 
2                            640                step 1               1                   1                   320                             32 
3                            640                step 1               1                   3                   160                             16 
4                            160                step 3               1                   1                     80                               8 
5                            160                step 3               0.5                1.5                  40                               4 
6                            160                step 3               0.5                3.5                  20                               2  
7                              20                step 6               1                   1                     10                               1 
8                              20                step 6               0.5                1.5                    5                               0.5 
9                              20                step 6               0.5                3.5                    2.5                            0.25 
10                            2.5               step 9               1                   1                       1.25                          0.125 
11                            2.5               step 9               0.5                1.5                    0.625                        0.0625 
12                            2.5               step 9               0.5                3.5                    0.3125                      0.03125 
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Scheme for preparing dilution series of water insoluble antifungal agents  
Antimicrobial solution 
Step Concentration 
(µg/ml) 
Source Volume 
(ml) 
Solvent 
(ml) 
Eg. DMSO 
Intermediate 
concentration 
(µg/ml) 
Final concentration 
at 1:100 
(µg/ml) 
1 1600 stock   1600     16 
2                          1600                stock                0.5                0.5                  800                            8 
3                          1600                stock                0.5                1.5                  400                            4 
4                          1600                stock                0.5                3.5                  200                            2 
5                            200                step 4               0.5                0.5                  100                            1 
6                            200                step 4               0.5                1.5                    50                             0.5 
7                            200                step 4               0.5                3.5                    25                             0.25  
8                              25                step 7               0.5                0.5                   12.5                           0.125 
9                              25                step 7               0.5                1.5                     6.25                         0.0625 
10                            25                step 7               0.5                3.5                     3.13                         0.0313 
 
DMSO = Dimethyl Sulfoxide  
One growth control well and one drug control well was also put in parallel for each isolate.   
INCUBATION:  
All microtitre plates were incubated at 35oC and examined after 46-50 hours for 
Candida sp and after 70-72 hours for C.neoformans. 
INTERPRETATION: 
Minimum inhibitory concentration is the lowest concentration of an antifungal that 
causes specified reduction in visible growth in antifungal (broth dilution) susceptibility 
test. The magnitude of reduction in visible growth is assessed using the following 
numerical score for each microdilution well: 
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Score 4- No reduction in visible growth 
Score 3- Slight reduction in visible growth  
Score 2-Prominent reduction in visible growth (~50% of growth control) 
Score 1- Slightly hazy 
Score 0 -Optically clear or absence of visible growth 
 MIC for Amphotericin B is read at the well which gives a 0 score  
 MIC for Azoles is read at the well which gives a score of 2       
 ATCC C.krusei 6258 (QC strain) and ATCC C.parapsilosis 90018 (reference 
strain) were also tested in parallel for determination of MIC. Recommended 48 hours MIC 
limits for ATCC C.krusei are 1 - 4µg/ml for amphotericin B, 16 – 128µg/ml for 
fluconazole and 0.12 – 1µg/ml for voriconazole. For ATCC C.parapsilosis, the MIC limits 
are 0.5 – 4µg/ml for amphotericin B, 1 – 4µg/ml for fluconazole and 0.03 – 0.25µg/ml for 
voriconazole. Further, ATCC C. neoformans 32045 was also tested in addition to the 
above two control strains. 
 The MIC of antifungal agent was interpreted according to the values given in the 
table below20 
Antifungal agent Susceptible (S) Susceptible Dose 
Dependent (S-DD) 
Resistant (R) 
Fluconazole  < 8 µg/ml 16-32 µg/ml >64 µg/ml 
Voriconazole < 1 µg/ml 2 µg/ml > 4 µg/ml 
For amphotericin B, the isolate is likely to be resistant if an MIC of >1 µg/ml is obtained  
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EPSILOMETER (E) TEST:  
E test was performed for determining MIC of amphotericin- B and fluconazole to 
cryptococcal isolates. E test strips of both the drugs were obtained from Hi Media, 
Mumbai. Disposable plastic plates of 90mm containing RPMI 1640 and 2% glucose agar 
to a depth of 4mm were used. All the cryptococcal isolates and ATCC C.neoformans were 
subcultured on SDA for 48 hours and a yeast suspension equivalent to turbidity of 1 
McFarland was prepared. A lawn culture of the suspension was made with a sterile swab 
and E strip was placed on the surface of the agar. The concentration gradient varied from 
0.002- 32µg/ml for amphotericin- B and 0.016-256 µg/ml for fluconazole. The plates were 
incubated at 350C for 72 hours. MIC is the point of intersection of the growth inhibition 
zone with the strip. For amphotericicn B, the MIC was read at the point of complete 
inhibition (100%) of growth while for fluconazole, MIC was read at the point of 
approximately 80% inhibition of growth. 
 For comparing the performance of E test with that of the reference microbroth 
dilution test, Essential agreement (EA) and Categorical agreement (CA) were calculated50. 
A testing system is said to have "essential agreement" when the method under evaluation 
has an MIC within ± one 2-fold dilution compared with the reference method for MIC 
determination. "Categorical agreement" is when the interpretive results (susceptible, 
intermediate, or resistant) between a new method under evaluation and a standard 
reference method are the same. It is possible for there to be essential agreement with 
categorical disagreement. When this occurs, it is considered a "minor error" and frequently 
results in an intermediate susceptibility with one method and susceptible or resistant with 
another method. For drugs without an intermediate category, there cannot be minor errors. 
A "major error" occurs when the testing method determines that the organism is resistant, 
but the reference method determines that the organism is susceptible. Finally, a "very 
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major error" occurs when the converse is true—the testing method indicates the organism 
is susceptible but the reference method indicates that the organism is resistant. 
DETERMINATION OF CD4 COUNT- CD4 count of the patients was 
determined using flow cytometer (Cyflow- Partec) 
STATISTICAL ANALYSIS- Statistical analysis was carried out using Statistical 
Package for Social Sciences (SPSS) version 20.0. The proportional data of this study were 
tested using Pearson’s Chi square analysis test χ2 
 
  
  
 
Results 
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RESULTS 
A total of 175 CSF samples were collected during the study period from HIV positive 
patients presenting with features of meningitis.  
 
TABLE 1- AGE AND SEX DISTRIBUTION OF HIV PATIENTS PRESENTING WITH 
FEATURES OF MENINGITIS (n=175) 
Age (years) Males (n) Females (n) 
10-20 2 1 
21-30 40 18 
31-40 57 14 
41-50 38 - 
51-60 4 - 
61-70 1 - 
 
 142  33 
 
The age of the patients varied from 14 to 65 years with a mean age of 38 yrs. Only 33 
(18.86%) of the 175 patients were females. 
            Among these HIV patients, 19 patients were diagnosed with cryptococcal meningitis 
(CM), of which, 16 were primary episodes and 3 were symptomatic relapse episodes. 
 
 TABLE 2- AGE AND SEX DISTRIBUTION OF PATIENTS WITH 
CRYPTOCOCCAL MENINGITIS 
Age (years) Primary episode (n=16)
Males
20-30 2
31-40 4
41-50 7
 
Among the 16 patients who presented with a primary 
meningitis, only 3 were females (18.75%). None of the female patients had a relapse 
episode during the study period
 
0 1
10-20 years
21-30 years
31-40 years
41-50 years
CHART 1- AGE AND SEX DISTRIBUTION OF PATIENTS 
WITH PRIMARY EPISODE OF CRYPTOCOCCAL 
46 
(n=19) 
 Relapse (n=3)
 Females Males 
 1 1 
 2 1 
 - 1 
episode of cryptococcal 
.                                  
 
2 3 4 5 6
MENINGITIS
 
Females 
- 
- 
- 
 
7
Females
Males 
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TABLE 3- DISTRIBUTION OF SIGNS AND SYMPTOMS IN  
CRYPTOCOCCAL MENINGITIS (n=19) 
Symptom/ Sign Primary episode  
[n= 16] (%) 
Relapse [n=3] 
(%) 
Total [n=19] 
(%) 
Headache 14 (87.5) 3 (100) 17 (89.47) 
Vomiting 9 (56.25) 3 (100) 12 (63.16) 
Fever 5 (31.25) 3 (100) 8 (42.11) 
Altered sensorium 6 (37.5) 1 (33.33) 7 (36.84) 
Neck rigidity 6 (37.5) 1 (33.33) 7 (36.84) 
Visual disturbances 3 (18.75) 1 (33.33) 4 (21.05) 
FND* 
- Paraparesis 
- Hemiparesis 
3 (18.75) 
2 (12.5) 
1 (6.25) 
- 3 (15.79) 
2 (10.53) 
1 (5.26) 
Papilledema 1 (6.25) 1 (33.33) 2 (10.53) 
Seizures (GTCS) 1 (6.25) - 1 (5.26) 
Skin lesions - 1 (33.33) 1 (5.26) 
Osteomyelitis 1 (6.25) - 1 (5.26) 
Autonomic 
dysfunction 
(urinary incontinence) 
1 (6.25) - 1 (5.26) 
*FND- Focal neurological deficit 
Headache was the predominant symptom observed in HIV patients presenting with 
symptoms of meningitis. 
 TABLE 4- TIME DURATION BETWEEN DIAGNOSIS OF HIV INFECTION AND 
FIRST EPISODE OF CRYPTOCOCCAL MENINGITIS (n= 16)
Diagnosis of HIV infection
On admission 
<6 months 
6- 12 months 
13- 24 months 
25-36 months 
>36 months 
                                                              
Majority of the patients presented between 1
Cryptococcal meningitis was the AIDS defining illness in 3 patients.  
3
CHART 2- DURATION BETWEEN DIAGNOSIS OF HIV 
INFECTION AND PRSENTATION WITH PRIMARY EPISODE 
OF CRYPTOCOCCAL MENINGITIS
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 No. of patients Percentage (%)
3 
2 
1 
4 
3 
3 
 
-2 years of diagnosis of HIV infection. 
 
3
3
1
4
3
 
 
18.75 
12.5 
6.25 
25 
18.75 
18.75 
 
On admission
<6 months
6- 12 months
13-24 months
25-36 months
>36 months
 TABLE 5- CORRELATION BETWEEN CRYPTOCOCCAL MENINGITIS 
AND PRIOR 
THERAPY (ART) AND/OR
Cryptococcal meningitis
(CM) 
First episode 
(n= 16) 
(n=3)* 
(n=13) 
Relapse (n=3) 
      *Patients diagnosed with HIV infection only after
More than half of the patients 
ART at the time of presentation
T.fluconazole as a prophylactic measure against opportunistic infections. Only one of the 
3 patients who presented with relapse had failed to take secondary fluconazole prophylaxis 
and was also not started on HAART.       
CHART 3- CORRELATION BETWEEN CM AND PRIOR INTAKE OF 
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TREATMENT WITH ANTI RETROVIRAL 
 PROPHYLACTIC FLUCONAZOLE
 No.of patients on ART No.of patients on 
T. Fluconazole
- 
9 (69.23%) 3 (23.07%)
2 (66.67%) 2 (66.67%)
 admission                                                            
with prior diagnosis of HIV infection 
 with CM. In addition, 3 patients were also receiving 
 
ART OR FLUCONAZOLE 
Patients on 
T.fluconazole
Patients on 
ART
PRIMARY 
EPISODE
(9/13)
RELAPSE
(2/3)
PRIMARY 
EPISODE
(3/13)
RELAPSE
(2/3)
 
 
 (n=19) 
ART and       
 
- 
 
 
 
were receiving 
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TABLE 6- BIOCHEMICAL ANALYSIS OF CSF IN CRYPTOCOCCAL 
MENINGITIS (n=19) 
CSF No. of Patients Percentage 
GLUCOSE  
 Reduced 
 Normal 
 Elevated 
 
6 
12 
1 
 
31.57 
63.15 
5.26 
PROTEIN 
 Reduced 
 Normal 
 Elevated 
 
Nil 
5 
14 
 
- 
26.31 
73.68 
Cell count* 
 Normal 
 Elevated 
 
2 
15 
 
10.52 
78.94 
*complete absence of cells in the CSF (n=2) 
Normal CSF glucose level in an adult is 40-70 mg/dl, protein is 15-40 mg/dl and 
cell count is <5 cells/µl. The CSF glucose level was normal in majority of the patients 
while protein and cell counts were elevated. 
 
  
 TABLE 7- COMPARISON OF 
MENINGITIS BY VARIOUS TESTS
 
Test Positive
India ink 
(68.75%)
Gram stain 
(43.75%)
Latex 
Agglutination Test 
(LAT) 
(100%)
Culture 
(75%)
LAT detected
0
2
4
6
8
10
12
14
16
India ink
Gram stain
11
2
CHART 4- DETECTION OF CRYPTOCOCCUS BY VARIOUS 
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DETECTION OF CRYPTOCOCCAL 
 (n=19) 
First episode (n=16) Relapse (n=3)
 Negative Positive 
11 
 
5 
(31.25%) 
2 
(66.67%) 
7 
 
9 
(56.25%) 
1 
(33.33%) 
16 
 
- 3 
(100%) 
12 
 
4 
(25%) 
1 
(33.33%) 
 capsular polysaccharide in all patients with CM
LAT
Culture
7
16
12
1
3
1
TESTS
 
Negative 
1 
(33.33%) 
2 
(66.67%) 
- 
2 
(66.67%) 
 
 
first episode (16)
relapse (3)
 TABLE 8– DURATION OF 
Duration of growth on SDA
<48 hours 
48- 72 hours 
>72 hours 
 
 
CHART 5- DURATION OF
Majority of the cryptococcal isolates grew within 72 hours of 
on SDA. However, one of the isolate grew on the 5
only.  
 
0
1
2
3
4
5
6
7
8
9
< 48 hours
2
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GROWTH OF CRYPTOCOCCAL 
ISOLATES ON SDA (n=13) 
 No. of isolates Percentage
2 
9 
2 
13 
 GROWTH OF CRYPTOCOCCAL 
ISOLATES ON SDA 
i
th
 day and another grew on the 7
48- 72 hours > 72 hours
9
2
 
 
15.38 
69.23 
15.38 
100 
 
 
noculation of CSF 
th
 day 
 TABLE 9- BIOCHEMICAL IDE
POS
Biochemical test
Hydrolysis of urea (n=13) 
Brown colonies on CFA medium
Growth on CGB medium (n=13)
Assimilation of D-proline (n=13)
Growth on CDBT medium
 
CFA- Caffeic acid ferric citrate agar, CGB
medium, CDBT- Creatinine Dextrose Bromothymol blue Thymine medium
All the 13 cryptococcal isolates hydrolysed urea and formed brown 
CFA medium. But only 1 isolate grew on CGB medium and assimilated proline.
13
0
2
4
6
8
10
12
14
Urease Brown colonies 
on CFA medium
CHART 6-
CRYPTOCOCCAL ISOLATES
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NTIFICATION OF CULTURE 
ITIVE CRYPTOCOCCAL ISOLATES 
 No. of isolates
Positive 
13 
 (n=13) 13 
 1 
 1 
 (n=12) 0 
- Canavanine Glycine Bromothymol blue 
13
1
0
Growth on CGB 
medium
Growth on CDBT 
medium
Assimilation of D
BIOCHEMICAL IDENTIFICATION OF 
 
 
Negative 
13 
13 
12 
12 
12 
 
 
colonies on 
 
1
-
proline
 TABLE 10- ASSIMILATION OF CARBOHYDRATES BY 
CRYPTOCOCCAL ISOLATES
Test isolates 
(13) 
 Inositol
C.neoformans 
(12) 
+ 12
- 
C.gattii  
(1) 
+ 
- 
                                      
 All the C.neoformans
sucrose. But 2 of them failed to assimilate cellobiose and none of the isolates assimilated 
lactose.  The C.gattii isolate assimilated inositol, dextrose, maltose and sucrose but not 
lactose and cellobiose.            
 
0
2
4
6
8
10
12
CHART 7-
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 (n=13) 
 Dextrose Lactose Maltose Sucrose
 12 0 12 
0 0 12 0 
1 1 0 1 
0 0 1 0 
 
 isolates assimilated inositol, dextrose, mal
 
 
inositol
dextrose
lactose
maltose
sucrose
cellobiose
12
1
12
1
0 0
12
1
12
1
10
0
ASSIMILATION OF CARBOHYDRATES BY 
CRYPTOCOCAL ISOLATES
 
 Cellobiose 
12 10 
0 2 
1 0 
0 1 
tose and 
 
 TABLE 11- TREATMENT RECEIVED BY PATIENTS FOR
EPISODE OF 
Treatment 
Amphotericin-B +  
5-Flucytosine 
Amphotericin-B alone
Amphotericin-B + Fluconazole
Others 
 
None of the patients received 5
meningitis. 6 of the 16 patients died during the primary episode
amphotericin-B and 1 patient died even before starting amphotericin
 
5- Flucytosine
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CRYPTOCOCCAL MENINGITIS (n=16)
No.of patients (n=16) Outcome
- 
 6 2-  survived, 4
 9 7- survived, 2
1 
-FC as part of primary therapy for Cryptococccal 
 despite institution of 
-B. 
Amphotericin- B
(15)
Fluconazole
(9)(0)
 FIRST  
 
 
- 
- died 
- died 
Died 
 
 CHART 8- CD4 COUNT OF 
TABLE 12- CORRELATION OF CD4 COUNT WITH SURVIVAL OF THE 
PATIENTS WITH CRYPTOCOCCAL MENINGITIS 
CD4 count 
(cells/µl)
<40 
40-100 
>100 
   *One patient died before estimation of the CD4 count
            For patients with a relapse episode of CM, CD4 count of th
shown in the above table. Majority of the patients 
the time of presentation with CM. 
death of the patient and a CD4 count 
0
20
40
60
80
100
120
140
160
54
63
56
42 35
32
151
*One patient died before estimation of the CD4 count.
Among patients with CM, the 1
13th patient each died during first episode itself while the 2
died during relapse
56 
PATIENTS WITH CRYPTOCOCCAL 
MENINGITIS* 
(n=16
 
No. of patients 
(n=15 + 1*) 
Survived Died
8 2 6 
6 5 1 
1 1 - 
 
e relapse episode is 
who died had CD4 count <
Statistically significant association was found between 
<40cells/µl (p= 0.018) 
34
9
32 31 34
56
115
25 24
62
89
st, 5th, 6th, 8th, 9
nd patient 
 
) 
 
40cells/µl at 
th and 
First episode
Relapse
 TABLE 13- MIC OF AMPHOTERICIN B
MICROBROTH DILUTION METHOD
 
Test isolates (13) 
 
0.03 0.06
C.neoformans (12)  - 
C.gattii (1) - 
 
There are no definitive susceptible CLSI breakpoints for amphotericin
cryptococcal strains. However, any isolate with MIC >1µg/ml is considered to be resistant 
to amphotericin-B.  The MIC of amphotericin
 
                                
 
0.12
0.25
0
0.1
0.2
0.3
0.4
0.5
0.6
C.neoformans (n=12)
CHART 9- MIC(µg/ml) OF AMPHOTERICIN
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 FOR CRYPTOCOCCAL ISOLATES
 (n=13) 
 
 MIC (µg/ml) 
 0.12 0.25 0.5 1 2 
- 2 9 1 - - 
- - - 1 - - 
-B varied from 0.12-0.5 µg/ml
 
0.5 0.5
C.gattii (n=1)
-B BY MICROBROTH 
DILUTION METHOD
 BY 
4 8 16 
- - - 
- - - 
-B to 
. 
 
n=2
n=9
n=1
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TABLE 14- MIC OF AMPHOTERICIN B FOR CRYPTOCOCCAL ISOLATES BY 
EPSILOMETER TEST (n=13) 
 
Test isolates (13) 
MIC (µg/ml) 
0.002 0.004 0.008 0.016 0.032 0.064 0.128 0.256 0.5 1 
C.neoformans (12)   - - - 2 3 2 4 1 - - 
C.gattii (1) - - - - - - 1 - - - 
                                 
MIC of amphotericin-B by E test varied from 0.016-0.256 µg/ml.  
TABLE 15- COMPARISON OF MIC LEVELS OF AMPHOTERICIN-B 
OBTAINED BY MICROBROTH DILUTION METHOD AND E TEST (n=13) 
MIC (µg/ml) 
Microbroth 
dilution 
method 
 
0.008 0.016 0.032 0.064 0.128 0.256 0.5 1 
C.neoformans 
(12) 
- - - - 2 9 1 - 
C.gattii (1) - - - - - - 1 - 
 
E test 
C.neoformans 
(12) 
- 2 3 2 4 1 - - 
C.gattii (1) - - - - - - 1 - 
 
Isolates of C.neoformans were found to have a relatively lower MIC for 
amphotericin-B when tested by E test in comparison with the microbroth dilution method. 
The essential agreement [EA] (MIC of E test within + one 2 fold dilution when compared 
with the reference microbroth dilution method) is 61.5% as 8 of the 13 cryptococcal 
isolates had MIC ranging from 0.064- 0.5 µg/ml which is within one 2 fold dilution of the 
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range obtained by the reference method (0.12-0.5 µg/ml). The categorical agreement [CA] 
(interpretive results: S, I, R are same between E test and reference microbroth dilution 
method) is 100% as all the cryptococcal isolates were susceptible to amphotericin-B by 
both microbroth dilution method and E test.  
Significant association was found between testing cryptococcal isolates with E test 
and obtaining lower MIC values <0.012 µg/ml for amphotericin-B compared to 
microbroth dilution method (p= 0.002) 
 
TABLE 16- MIC OF FLUCONAZOLE FOR CRYPTOCOCCAL ISOLATES BY 
MICROBROTH DILUTION METHOD (n=13) 
 
Test isolates (13) 
  MIC (µg/ml) 
0.12 0.25 0.5 1 2 4 8 16 32 64 
C.neoformans (12)   - - 5 6 1 - - - - - 
C.gattii (1) - - - - 1 - - - - - 
                                                           
According to CLSI M27-A3, cryptococcal isolates tested by microbroth dilution 
method and exhibiting MIC <8 µg/ml are susceptible, 16-32 µg/ml are susceptible- dose 
dependant and >64 µg/ml are resistant to fluconazole respectively. The MIC of 
fluconazole varied from 0.5-2 µg/ml. 
 
 
 
 
  
 
 
TABLE 17- MIC OF FLUCONAZOLE FOR CRYPTOCOCCAL ISOLATES BY 
 
Test isolates (13) 0.16 
C.neoformans (12)   - 
C.gattii (1) - 
                                               
MIC of fluconazole by E test varied from 1
 
0.25
0.5
0
0.5
1
1.5
2
2.5
C.neoformans (n=12)
CHART 10- MIC (µg/ml ) OF FLUCONAZOLE BY MICROBROTH 
60 
EPSILOMETER TEST (n=13) 
 
MIC (µg/ml) 
0.32 0.64 0.128 0.256 0.5 
- - - - - 
- - - - - 
 
-8 µg/ml 
 
2 2
C.gattii (n=1)
DILUTION METHOD
 
1 2 4 8 
3 3 4 2 
- - - 1 
n=5
n=6
n=1
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TABLE 18- COMPARISON OF MIC LEVELS OF FLUCONAZOLE OBTAINED 
BY MICROBROTH DILUTION METHOD AND E TEST (n=13) 
MIC (µg/ml) 
Microbroth 
dilution 
method 
 0.128 0.256 0.5 1 2 4 8 16 
C.neoformans 
(12) 
- - 5 6 1 - - - 
C.gattii (1) - - - - 1 - - - 
 
E test 
C.neoformans 
(12) 
- - - 3 3 4 2 - 
C.gattii (1) - - - - - - 1 - 
 
Isolates of both C.neoformans and C.gattii were found to have a relatively higher 
MIC for fluconazole when tested by E test in comparison with the microbroth dilution 
method. The essential agreement [EA] is 76.9% as 10 of the 13 cryptococcal isolates had 
MIC ranging from 1- 4µg/ml which is within one 2 fold dilution of the range obtained by 
the reference method  (0.5-2 µg/ml). The categorical agreement [CA] is 100% as all the 
cryptococcal isolates were susceptible to fluconazole by both microbroth dilution method 
and E test.  
Significant association was observed between testing cryptococcal isolates by E 
test and obtaining higher MIC values >4µg/ml for fluconazole compared to microbroth 
dilution method (p=0.008). 
 
 
 TABLE 19- MIC OF VORICONAZOLE 
MICROBROTH DILUTION METHOD
 
Test isolates (13) 0.03 
C.neoformans (12) - 
C.gattii (1) - 
 
According to CLSI M27
method and exhibiting MIC 
dependant and >4 µg/ml are resistant to voriconazole respectively
voriconazole varied from 0.06
All the cryptococcal isolates were sensitive to voriconazole by microbroth dilution 
method with MIC <1µg/ml
0.06
0.12
0
0.05
0.1
0.15
0.2
0.25
0.3
C.neoformans (n=12)
CHART 11- MIC(
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FOR CRYPTOCOCCAL ISOLATES 
 (n=13) 
MIC (µg/ml) 
0.06 0.12 0.25 0.5 1 2 
4 7 1 - - - 
- - 1 - - - 
-A3, cryptococcal isolates tested by microbroth dilution 
<1 µg/ml are susceptible, 2 µg/ml are susceptible
-0.25µg/ml.          
. 
 
0.25 0.25
C.gattii (n=1)
µg/ml) OF VORICONAZOLE BY MICROBROTH 
DILUTION METHOD 
BY 
4 8 16 
- - - 
- - - 
- dose 
. The MIC of 
 
n=4
n=7
n=1
 TABLE 20- SUSCEPTIBILITY PATTERN OF CRYPTOCOCCAL ISOLATES TO 
Antifungal drug 
Amphotericin- B 
Fluconazole 
Voriconazole 
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CHART 12- PERCENTAGE OF CRYPTOCOCCAL ISOLATES 
SUSCEPTIBLE TO ANTIFUNGAL DRUGS
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ANTIFUNGAL AGENTS (n=13) 
 
Microbroth dilution method 
(Susceptible isolates in %) (Susceptible isolates in %)
100 
100 
100 Not tested
 
Voriconazole
microbroth dilution method
E test
E test 
 
100 
100 
 
 
FIGURE 1- SWELLING OF LEFT HAND IN A PATIENT WITH 
OSTEOMYELITIS OF FIRST METACARPAL BONE
FIGURE 2- MRI SCAN OF THE PATIENT SHOWING PRESENCE OF 
HYPODENSE LESION AT THE BASE OF LEFT FIRST METACARPAL BONE
 
 
 
 
 
 
 
FIGURE 3- CUTANEOUS LESIONS IN A PATIENT WITH DISSEMINATED 
CRYPTOCOCCAL INFECTION 
 
 
FIGURE 4- CT SCAN SHOWING DILATED VENTRICLES IN A PATIENT 
WITH OBSTRUCTIVE HYDROCEPHALUS SECONDARY TO CHRONIC CM
 
FIGURE 5- INDIA INK PREPARATION SHOWING PRESENCE OF 
CAPSULATED BUDDING YEAST CELLS IN THE CSF 
 
FIGURE 6- MODIFIED INDIA INK PREPARATION WITH 2% 
MERCUROCHROME SHOWING THE 3 LAYERS OF THE  
CAPSULE OF CRYPTOCOCCUS 
 
FIGURE 7- GRAM POSITIVE CAPSULATED BUDDING YEAST  
CELLS IN THE CSF 
 
 
FIGURE 8- LATEX AGGLUTINATION TEST POSITIVE FOR 
CRYPTOCOCCAL POLYSACCHARIDE IN THE CSF 
 
FIGURE 9- SDA SLOPES SHOWING GROWTH OF CRYPTOCOCCUS 
FIGURE 10- SDA PLATE WITH CRYPTOC
FROM CSF  
 
OCCUS ISOLATED FROM 
SKIN LESION 
 
 
 
FIGURE 11- CONTROL STRAINS USED FOR BIOCHEMICAL REACTIONS 
 
 
FIGURE 12- TEST ISOLATE SHOWING A POSITIVE UREASE REACTION
 
FIGURE 13- GROWTH OF CRYPTOCOCCUS ON CAFFEIC ACID MEDIUM 
 
 
FIGURE 14- CFA MEDIUM SHOWING BROWN COLONIES OF 
CRYPTOCOCCUS NEOFORMANS AND WHITE COLONIES OF  
CANDIDA ALBICANS 
 
Left- ATCC C.neoformans (Positive control), Bottom- ATCC C.albicans (Negative 
control), Top- Test isolate 
FIGURE 15- GROWTH OF CRYPTOCOCCUS ON CGB MEDIUM 
 
Left- C.gattii (positive control), Right- ATCC C.neoformans (negative control),                        
Middle- Test isolate 
FIGURE 16- CGB AGAR PLATE WITH GROWTH OF C.GATTII ISOLATE 
 
FIGURE 17- CDBT MEDIUM USED FOR VARIETY DIFFERENTIATION OF 
CRYPTOCOCCUS NEOFORMANS 
 
 
 
FIGURE 18- AUXANOGRAPHIC TECHNIQUE FOR ASSIMILATION OF 
CARBOHYDRATES BY CRYPTOCOCCUS NEOFORMANS 
 
  
FIGURE 19- ABSENCE OF ASSIMILATION OF PROLINE BY TEST ISOLATE 
OF CRYPTOCOCCUS NEOFORMANS 
 
 
FIGURE 20- ASSIMILATION OF PROLINE BY TEST ISOLATE OF 
CRYPTOCOCCUS GATTII 
 
 
  
FIGURE 21- DETERMINATION OF AMPHOTERICIN- B MIC BY 
MICROBROTH DILUTION METHOD 
 
 
FIGURE 22- MIC DETERMINATION OF AMPHOTERICIN- B USING E TEST 
 
  
FIGURE 23- DETERMINATION OF FLUCONAZOLE MIC BY MICROBROTH 
DILUTION METHOD 
 
 
FIGURE 24- MIC DETERMINATION OF FLUCONAZOLE BY E TEST
 
FIGURE 25- DETERMINATION OF VORICONAZOLE MIC BY MICROBROTH 
DILUTION METHOD 
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DISCUSSION 
Before the advent of the AIDS pandemic, relatively few cases of infections due to 
C.neoformans were reported and the rise in incidence of cryptococcosis paralleled the rise 
in HIV infection19. In a study carried out at PGIMER- Chandigarh, the annual incidence of 
CM increased 15 fold in 1995-99 when compared to 1970-82 synchronous with the spread 
of HIV cases in India15. Another study carried out at AIIMS, New Delhi (1992-2004) 
showed that HIV- Cryptococcus co-infection rose from 20% in 1992 to 49% in 2004. 
However, with early recognition of HIV infection and widespread access to ART, the 
incidence of cryptococcosis is now on the decline. In a report from France, the incidence 
of CM has declined by 46% in 1997-2001 when compared to 1985-1996 21. In India too, 
due to the active intervention by NACO and implementation of NACP, there has been an 
appreciable fall in the incidence of not only CM but all other opportunistic infections as 
well in patients with AIDS70. The prevalence of CM in HIV reactive patients was found to 
be 10.86% in this study. It is lower when compared to 12.9% in a study by Nigam et al 
conducted between March 2009 and February 2012 at BHU, Varanasi70.  
 Majority of patients in this study were males (81.25%) similar to other studies in 
India and elsewhere (Table 2). Male to female ratio of 5.3:1 was observed. Cryptococcal 
meningitis is more frequently observed in men than women42, 44, 81 and may reflect 
differences in exposure rather than susceptibility76. Most of the patients affected with CM 
in this study were in the age group of 41-50 years (43.75%) which is higher when 
compared to other studies. In a study by Thakur et al, 53% of patients were <40 years and 
only 15% were in the age group of 40-50 years92.  
 Headache lasting more than a week was the predominant symptom (89.47%) in 
most of the patients in this study (Table 3). This is comparable to a study by Chakrabarti et 
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al where headache was seen in 90% of patients49 and another study by Lakshmi et al 
where 92.31% of patients presented with headache55. Vomiting was noticed in 63.16% of 
patients while fever was observed in 42.11% of patients. Altered sensorium and/or 
terminal neck stiffness was seen in 36.84% of patients. However, Chakrabarti et al 49 and 
Lakshmi et al 55had found altered sensorium in 45% and 71.79% of their patients 
respectively. Visual disturbances, predominantly blurring was noticed in 21.05% of 
patients in this study. Thakur et al had found diplopia in 16.7% of patients in their study92. 
Papilledema was observed in 10.53% of patients which is comparable to 9% found in a 
study by Aslam et al 5. Motor deficits (para/hemiparesis) were seen in 15.79% of patients. 
In this study, seizures were noticed in only one patient who presented with 2 episodes of 
GTCS. Autonomic disturbance in the form of urinary incontinence was found in one of the 
patients. Previous reports too have described the occurrence of myelitis- like syndrome in 
cryptococcal meningitis34. Findings of CT scans were non- specific except for presence of 
obstructive hydrocephalus in one patient. In addition to the above features of meningitis, 
extrameningeal symptoms were found in two patients in this study. One patient presented 
with 10 days duration of cutaneous manifestations in the face, chest and back. On 
examination, several papulovesicular lesions were seen in the involved areas of the skin. It 
has been reported that involvement of the skin is a marker of disseminated cryptococcal 
infection until proved otherwise. Varied skin manifestations can occur in cryptococcosis 
including macules, papules, plaques, nodules, vesicles or ulcers22. Culture of swabs taken 
from the base of the vesicle in this patient yielded growth of yeast like colonies on SDA in 
72 hours. The other patient with disseminated infection presented with a vague, painful 
swelling in the left hand of 2 months duration. MRI showed a hypodense cortical lesion at 
the base of the 1st metacarpal surrounded by hypodense areas in the soft tissue of the left 
hand. After treating the patient for CM, a sequestrectomy of the involved bone was 
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performed with clinical diagnosis of osteomyelitis which also grew yeast like colonies on 
SDA. The yeast like isolates obtained from skin and bone of the two patients were 
identified as C.neoformans based on hydrolysis of urea and production of brown colonies 
on CFA.  
 The duration between diagnosis of HIV infection and occurrence of primary 
episode of cryptococcal meningitis was less than 2 years in 7 of the 16 patients (Table 4). 
In 3 patients, a diagnosis of HIV infection was made only after admission with symptoms 
of meningitis. So, in this study CM was the AIDS defining illness in 18.75% of patients. 
Earlier studies showed a higher rate and in a study by Chakrabarti et al CM was the AIDS 
defining illness in 75% of their patients49. The fact that only 3 patients in this study were 
unaware of their HIV status reflects the trend of earlier diagnosis of HIV infection in the 
community.  
 Among the 13 patients in whom a diagnosis of HIV infection was made prior to the 
presentation with CM, 9 (69.23%) were on ART (Table 5). The duration of prior treatment 
with ART by the patients varied from 1 month to 2 years. Moreover, 3 (23.07%) patients 
were also on T. fluconazole in addition to ART as a prophylactic measure against 
opportunistic infections. Despite the intake of these drugs, the patients developed CM 
probably owing to their low CD4 counts (<100/µl) which failed to contain the infection. In 
a study by Baradkar et al 6 conducted between 2006 and 2007, only 21.05% of patients 
with CM were on prior ART. These findings reiterate that there is better availability and 
wider access to ART among HIV reactive cohorts.  
 Biochemical analysis of CSF showed normal glucose levels in majority (63.15%) 
of the patients (Table 6). However, protein and cell counts were found to be elevated in 
73.68% and 78.94% of patients respectively in this study. In patients with raised cell 
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counts, the predominant cells were lymphocytes. No cells could be detected in the CSF of 
2 (10.5%) patients. Chakrabarti et al had found total absence of cells in the CSF of 50% of 
patients in their study49. It is well known that the CSF findings in CM can be non-specific. 
But sometimes lowered glucose levels or elevated protein/ cell counts are encountered. 
 The positivity rate of detection of Cryptococcus in the CSF varied between the 
diagnostic tests used in this study (Table 7). Among the 16 patients who presented with 
primary episode of CM, India ink preparation was positive in 11 (68.75%), LAT in 16 
(100%) and culture in 12 (75%). Gram stain however, showed budding yeast like 
organisms (YLO) in only 7 (43.75%) patients. In a study by Imwidthaya et al37, the 
positivity of India ink, LAT and culture for Cryptococcus were 91%, 100% and 100% 
respectively. However, Nigam et al70 had found positivity rate of 70% (India ink), 100% 
(LAT) and 85% (culture) which is comparable to the results obtained in this study. 
 Among the 4 patients whose culture was negative for Cryptococcus, 2 were started 
on empiric amphotericin-B before lumbar puncture was performed. This was done in the 
interest of the patients as it is well known that the disease is associated with a high 
mortality rate. In the other 2 patients, the exact reason for failure to grow the yeast could 
not be exactly ascertained. It is likely that the organism burden in the CSF of these patients 
could have been low or an insufficient volume of CSF was cultured.  
 In this study, there were 3 relapse cases accounting for 15.79% of the total cases 
admitted with CM. In a study by Jarvis et al, relapse was seen in 23% of CM cases 
admitted to their hospital40. Among the 3 patients who presented with a relapse episode, 
India ink, LAT & culture was positive in 2 (66.67%), 3 (100%) and 1 (33.33%) 
respectively. In this study, the first patient among the 3 who had an episode of relapse had 
discontinued secondary prophylaxis and presented with a relapse 4 months later. During 
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this episode, he succumbed to the infection. It is estimated that without secondary 
prophylaxis, atleast 50-60% of patients with CM will have disease relapse19.98. When 
administered properly, secondary prophylaxis with fluconazole is highly effective, 
increasing recurrence free survival by over thirteen fold at six months13, 80. In this study, 
the other 2 patients with relapse had received fluconazole prophylaxis. HAART was 
started 6 weeks after the primary episode in one patient and after 8 weeks in the other 
patient. So, the relapse in these 2 patients was due to IRIS. Therefore, IRIS accounted for 
10.5% of the total cases admitted with CM in this study. The former patient presented with 
IRIS after 43 days of starting HAART while the latter developed IRIS after 135 days of 
starting HAART. The median duration between starting HAART and development of IRIS 
in these patients was 89 days. India ink was positive in one patient while culture for 
Cryptococcus was negative in both these patients. There was no mortality observed and 
both of them are still under follow up. In a study by Jarvis et al, IRIS accounted for 10.3% 
of all CM cases occurring at a median of 61 days after commencement of HAART40. In 
Aslam et al study, 4% of patients presented with IRIS which occurred at a median of 120 
days after initiation of HAART 5. A multicentre prospective study published in 2009 
concluded that a large proportion of HIV positive patients with CM may develop an IRIS 
illness after starting HIV treatment but the increased likelihood of successful outcome 
when using HAART could outweigh the risks of developing IRIS in these patients. 
 In this study, culture of CSF on SDA showed mucoid, cream coloured, yeast like 
colonies within 48 hours in 2 samples while 9 samples grew yeast like colonies in    48-72 
hours (Table 8). In the remaining 2 culture positive samples, growth was observed on the 
5th and 7th day respectively. Delayed growth of Cryptococcus varying from 5-14 days has 
been previously noted in other studies as well42, 45.   
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 In this study, urea was hydrolysed within 24 hours on Christensen’s urease 
medium by all the 13 cryptococci isolated from CSF of patients with CM (Table 9). In 
addition, all these isolates also formed brown colonies on CFA medium. The duration for 
production of pigment varied from 2-4 days. For speciating the cryptococci, the isolates 
were subcultured on CGB medium and also tested for their ability to assimilate proline. 12 
out of the 13 cryptococci isolated in this study neither grew on CGB medium nor 
assimilated proline indicating that they were C.neoformans. There are only few reports of 
C.gattii causing meningitis in HIV patients, and in this study, C.gattii was isolated from a 
single patient (7.69%). In most of the studies including that by Baradkar et al 6 and 
Manoharan et al 63, all the cryptococcal isolates were C.neoformans. However, Nigam et 
al found that5.88% of cryptococci isolated from HIV positive patients in their study were 
C.gattii 70. For determining the varietal status, the 12 isolates of C.neoformans were also 
subcultured on CDBT medium. All the 12 isolates failed to grow on this medium 
indicating their inability to assimilate thymine. Therefore, all the isolates in this study 
were found to be C.neoformans var. grubii. Both, in India and globally, greater than 90% 
of cryptococcal infections in HIV patients are caused by C.neoformans var. grubii 
(serotype A) 65. The findings of this study were therefore, consistent with those of the 
earlier ones. 
 The result of assimilation of carbohydrates showed that all 12 C.neoformans 
isolates assimilated inositol, dextrose, maltose and sucrose but none of them assimilated 
lactose. Cellobiose, however, was assimilated by only 10 of the isolates (Table 10). The 
C.gattii isolate assimilated inositol, dextrose, maltose and sucrose but not lactose and 
cellobiose. It is well known that C.neoformans and C.gattii do not assimilate lactose. 
Assimilation of cellobiose, however, varies between individual strains27.  
70 
 
 Due to scarce availability of 5-flucytosine (5-FC), none of the patients in this study 
received amphotericin-B + 5-FC in combination for induction phase therapy of CM         
(Table 11). But 15 of the 16 patients who presented with primary episode of CM received                
intravenous amphotericin-B, 6 in the form of monotherapy and 9 in combination with oral 
fluconazole. One patient expired before a diagnosis of CM was made and had only 
received intravenous ceftriaxone. However, despite institution of amphotericin-B, 6 
patients died during the primary episode itself. The mortality rate observed for primary 
episodes of CM was 43.75%. The remaining 9 patients were started on secondary 
fluconazole prophylaxis but one patient discontinued it and presented with relapse later 
and died. So, overall mortality of 42.1% due to CM was observed in this study. This is 
higher when compared to mortality rate of 25.64% found by Lakshmi et al 55 and 15% 
found by Nigam et al 70 in their studies respectively.  
 Estimation of the CD4 count at the time of presentation with primary episode of 
CM showed that 14 out of 15 patients had counts <100cells/µl and only one patient had a 
count of 115cells/µl (chart 8). One patient died before estimation of the CD4 count. In this 
study, the mean CD4 count of patients who survived the infection was 71.63cells/µl while 
the mean CD4 count of patients who succumbed to the infection was 34.71cells/µl. 
However, both Aslam et al 5 and Mahale et al 61 had found mean CD4 count of 60cells/µl 
in their studies.  It was observed that 75% of patients with CD4 count <40cells/µl died 
while only 14.28% of patients with CD4 count >40cells/µl died (Table 12). The 
association between death of patients with CD4 count <40cells/µl compared to those with 
CD4 counts >40cells/µl was found to be statistically significant (p = 0.018). Among the 3 
patients who had an episode of relapse, one showed deterioration in CD4 count from 63 to 
32 while the other 2 patients documented a rise in CD4 count from 56 to 151 and 9 to 89 
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respectively. The two patients with rise in CD4 counts had relapse due to IRIS and 
survived the episode but the other patient died.  
 Antifungal susceptibility testing was performed by microbroth dilution reference 
method of CLSI as per M27-A3 protocol20. MIC of amphotericin-B, fluconazole and 
voriconazole was determined for all the isolates obtained in CSF culture. All the 
C.neoformans and C.gattii were sensitive to amphotericin-B with MIC ranging from 0.12- 
0.5µg/ml using microbroth dilution method (Table 13) and 0.016-0.256µg/ml using 
epsilometer test (Table 14). Isolates of C.neoformans had relatively lower MIC values 
with the E test for amphotericin-B when compared with the microbroth dilution method 
(Table 15). Significant association (p=0.002) was observed between testing cryptococcal 
isolates by E test and obtaining lower MIC values <0.12µg/ml for amphotericin-B. 
Essential agreement (EA) between MIC values obtained by E test when compared with the 
reference microbroth dilution test was 61.5% for amphotericin-B in this study. In a study 
by Tewari et al 91, EA of 76% for MIC of amphotericin-B obtained by E test when 
compared to microbroth dilution test was found against 62 Indian clinical isolates of 
C.neoformans var.grubii. However, categorical agreement of 100% was observed both in 
this study and in the one conducted by Tewari et al 91. 
 All the C.neoformans and C.gattii were also sensitive to fluconazole with MIC 
ranging from 0.5- 2µg/ml using microbroth dilution method (Table 16) and 1-8µg/ml 
using epsilometer test (Table 17). However, in contrast to amphotericin-B, isolates of both 
C.neoformans and C.gattii exhibited relatively higher MIC values with the E test for 
fluconazole when compared with the microbroth dilution method (Table 18). Significant 
association (p=0.008) was observed between testing cryptococcal isolates by E test and 
obtaining higher MIC values >4µg/ml for fluconazole. Essential agreement of 76.9% for 
MIC values of fluconazole between E test and reference method was found in this study. 
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Tewari et al 91had found EA of 82.2% for fluconazole in their study. Categorical 
agreement (CA) of 100% for fluconazole was observed in this study while Tewari et al 91 
had found CA of only 77.4% between E test and reference method for fluconazole in their 
study.The variations in MIC values obtained with the E test for both amphotericin-B and 
fluconazole make it imperative that cryptococcal isolates be tested with the microbroth 
dilution method as recommended by the CLSI. 
 All cryptococcal isolates were sensitive to voriconazole too and the MIC values 
ranged from 0.06-0.25µg/ml  (Table 19).The sensitivity of cryptococcal isolates to 
antifungal agents was found to be 100% in this study (Table 20). As of now, resistance of 
C.neoformans to antifungal agents is very rare4, 11, 67 and even in the global scenario, only 
sporadic reports of resistance to fluconazole have been documented18, 48.                    
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SUMMARY 
 A total of 175 HIV positive patients presenting with features of meningitis were 
included in this study. 19 of them were found to have cryptococcal meningitis of which 16 
were primary episodes and 3 were episodes of relapse. The prevalence of cryptococcal 
meningitis was 10.58%. Majority of patients were males (81.25%) with a male to female 
ratio of 5.3:1. Most of the affected patients were in the age group of 41-50 years. 
Headache was the predominant presenting symptom occurring in 89.47% of 
patients followed by vomiting in 63.16% and fever in 42.11% of patients. Altered 
sensorium and neck stiffness were seen in 36.84% of patients each. Blurring of vision and 
motor deficits were observed in 21.05% and 15.79% of patients respectively. Papilledema 
was noted in 10.53% of patients. One patient each had an episode of seizure and urinary 
incontinence respectively. In addition to features of meningitis, two patients presented 
with disseminated infection of whom one patient had papulovesicular skin lesions and the 
other had osteomyelitis of the left 1st metacarpal bone. 
 The time between diagnosis of HIV infection and presentation with primary 
episode of cryptococcal meningitis was between 1- 2 years in most of the patients. CM 
was the AIDS defining illness in 3 patients. Moreover, 9 patients were on ART at the time 
of presentation with first episode of CM and 3 patients were also taking T. fluconazole in 
addition to ART.  
 Biochemical analysis of CSF in cases of CM showed normal glucose levels in 
63.15% of patients. Elevated protein levels were seen in 73.68% of patients and elevated 
cell counts were observed in 78.94% of patients. Lymphocytes were the predominant cell 
type observed. Total absence of cells in the CSF was noticed in 2 patients. 
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 Among patients who presented with primary episode of CM, India ink preparation 
was positive in 11 (68.75%), LAT was positive in 16 (100%) and culture was positive in 
12 (75 %). Among patients presenting with relapse, India ink preparation was positive in 2 
(66.67%), LAT was positive in 3 (100%) and culture was positive in 1 (33.33%). Growth 
of Cryptococcus on SDA was observed within 72 hours in all except two CSF samples 
which grew on the 5th and 7th day respectively. 
 Relapse episodes in 2 patients were due to IRIS occurring at a median of 89 days 
after the commencement of HAART. One patient developed relapse due to discontinuation 
of secondary fluconazole prophylaxis.    
All the 13 isolates of Cryptococcus obtained from culture of CSF hydrolysed urea 
and produced brown colonies on CFA. Of the 13 cryptococcal isolates, 12 were 
C.neoformans and only one was C.gattii.  The variety differentiation on CDBT medium 
showed that all the 12 C.neoformans isolated in this study belonged to C.neoformans var. 
grubii. 
All the 12 C.neoformans isolates assimilated inositol, dextrose, maltose and 
sucrose but none of them assimilated lactose. Cellobiose, however, was assimilated by 
only 10 of the isolates. The C.gattii isolate assimilated inositol, dextrose, maltose and 
sucrose but not lactose and cellobiose. 
            In the treatment of primary episode of CM, none of the patients received 
combination therapy of amphotericin-B with 5-flucytosine. But, 6 patients received 
intravenous amphotericin-B as monotherapy while 9 patients received intravenous 
amphotericin-B and oral fluconazole in combination. One patient died before starting 
amphotericin-B itself while 6 more patients died despite institution of amphotericin-B. In 
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addition, another patient died during the relapse episode. The overall mortality rate 
observed was 42.1%. 
            All except one patient had CD4 count <100cells/µl at the time of presentation with 
primary episode of CM. The mean CD4 count of patients who survived the infection was 
71.63cells/µl while the mean CD4 count of patients who succumbed to the infection was 
34.71cells/µl. The association between death of patients with CD4 count <40cells/µl 
compared to those with counts >40cells/µl was found to be statistically significant    
(p = 0.018). Two patients who had relapse due to IRIS showed elevated CD4 counts 
compared to their respective count in the primary episode.   
            Antifungal susceptibility testing performed by microbroth dilution method showed 
that all C.neoformans and C.gattii isolates were susceptible to the antifungal agents tested. 
For amphotericin-B, the MIC values ranged from 0.12- 0.5µg/ml using microbroth 
dilution method and 0.016-0.256µg/ml using epsilometer test. Significant association 
(p=0.002) was observed between testing cryptococcal isolates by E test and obtaining 
lower MIC values <0.12µg/ml for amphotericin-B. Essential agreement (EA) of 61.5% 
and Categorical agreement (CA) of 100% for amphotericin-B was found in this study. For 
fluconazole, the MIC values ranged from 0.5- 2µg/ml using microbroth dilution method 
and 1-8µg/ml using epsilometer test. Significant association (p=0.008) was observed 
between testing cryptococcal isolates by E test and obtaining higher MIC values >4µg/ml 
for fluconazole. EA of fluconazole was 76.9% while the CA was 100%.The MIC values 
ranged from 0.06-0.25µg/ml for voriconazole by microbroth dilution method. 
  
  
 
Conclusion 
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CONCLUSION 
 There is a decline in the number of cases of cryptococcal meningitis due to better 
diagnostic facilities for early detection of HIV infection and wider accessibility to ART. 
Male patients are more often affected and the symptoms of CM overlap with those due to 
other pathogens. Microscopic examination of CSF by India ink preparation is cost 
effective in the diagnosis of CM in HIV positive patients. LAT is highly sensitive in 
detecting cryptococcal polysaccharide in laboratories where the facility is available. 
Culture of CSF is the gold standard test in the diagnosis of CM and must be performed on 
all suspected cases of meningitis. C.neoformans is more often the etiologic agent of CM in 
HIV positive patients when compared to C.gattii. Treatment of patients with CM using 
amphotericin-B at the earliest is needed to reduce the mortality which is still unacceptably 
high. Secondary fluconazole prophylaxis must be started in all patients with CM to 
reduce/prevent the occurrence of relapse. Institution of HAART must be done after 
treatment of the primary episode as the benefits outweigh the risk of development of IRIS 
in these patients. CM often occurs when CD4 count falls below 100cells/µl. So, initiation 
of ART at CD4 count of 350cells/µl as recommended by the recent NACO guidelines can 
go a long way in further reduction of incidence of CM. Although resistance of 
C.neoformans to antifungal agents is rare, periodic monitoring of MIC by microbroth 
dilution tests is essential to notice any shifts in sensitivity pattern of clinical isolates.   
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ABBREVIATIONS 
AIDS Acquired Immuno Deficiency Syndrome 
ART- Anti Retroviral Therapy 
ATCC- American Type Culture Collection 
BAL- BronchoAlveolar Lavage 
CD4- Cluster of Differentiation 4 
CDBT- Creatinine Dextrose Bromothymol blue Thymine 
CFA- Caffeic acid Ferric citrate agar 
CGB- Canavanine Glycine Bromothymol blue 
CLSI- Clinical and Laboratory Standards Institute 
CM- Cryptococcal Meningitis 
CNS- Central Nervous System 
CRAG- Cryptococcal Antigen 
CSF- Cerebrospinal fluid 
CT- Computed Tomography 
EIA- Enzyme Immunoassay 
GTCS- Generalised Tonic Clonic Seizures 
HAART- Highly Active Anti Retroviral Therapy 
HIV- Human Immunodeficiency Virus 
ICT- Intracranial Tension 
IRIS- Immune Reconstitution Inflammatory Syndrome 
KOH- Potassium hydroxide 
LAT- Latex Agglutination Test 
LCB- Lactophenol Cotton Blue 
MIC- Minimum Inhibitory Concentration 
MRI- Magnetic Resonance Imaging 
NACO- National AIDS Control Organisation 
NACP- National AIDS Control Program 
QC- Quality Control 
RPMI- Rosewell Park Memorial Institute 
SDA- Sabouraud Dextrose Agar 
YCB- Yeast Carbon Base 
YLO- Yeast like Organism 
YNB- Yeast Nitrogen Base 
  
APPENDIX- I 
 (STAINS, REAGENTS AND MEDIA) 
 
 
I. GRAM STAINING 
Methyl violet (2%)            l0g Methyl violet in l00ml absolute alcohol in 1litre of 
distilled               
                                           water (primary stain) 
            Gram’s Iodine                   l0g Iodine in 20g KI (fixative) 
            Acetone                             (decolourising agent) 
            Carbol fuchsin 1%            (counter stain) 
 
II. INDIA INK 
            India ink                             150ml 
            Merthiolate (1:1000)                3ml 
           Tween 80 (1: 10,000)           0.1ml 
 
III. 10% KOH 
            Potassium hydroxide           10 g 
            Glycerol                               10 ml 
            Distilled water                      80 ml 
 
1. SABOURAUD DEXTROSE AGAR (SDA) 
Glucose                               40gm 
Peptone                                10gm 
Agar                                     20gm 
Distilled water                     1000ml 
Mix the reagents by boiling. Dispense in tubes and autoclave at 1210C for 15 minutes. 
Final pH must be 5.5 – 5.6. Allow the tubes to cool in slanted position. 
 
2. CHRISTENSEN’S UREASE TEST MEDIUM 
Peptone                                                          1g 
Sodium chloride                                            5g 
Dipotassium hydrogen phosphate                 2g 
Phenol red                                                    6ml 
Agar                                                             20g 
Distilled water                                              1 ltr 
10% sterile solution of glucose                   l0ml 
Sterile 20% urea solution                           l00ml 
Sterilize the glucose and urea solutions by filtration. Prepare the basal medium without 
glucose and urea, adjust to pH 6.8-6.9 and sterilize by autoclaving in a flask at 121°C for 
30min. Cool to about 50°C, add the glucose & urea, and tube the medium as slopes. 
3. CAFFEIC ACID FERRIC CITRATE MEDIUM 
Ingredient                                                     gm/ltr 
Yeast extract                                                   2 
Dextrose                                                          5 
Ammonium sulphate                                       5 
Dipotassium phosphate                                    5 
Magnesium sulphate                                        0.7 
Caffeic acid                                                      0.18 
Ferric citrate                                                     0.02 
Agar                                                                 20 
    pH 6.5 + 0.2 
Suspend 33.7 grams in 1 litre of distilled water. Heat until the solution boils to dissolve the 
contents completely. Sterilize by autoclaving at 1210C for 15 minutes. Cool to 550C, add 
chloramphenicol 50µg/ml and dispense in plates/ tubes 
  
4. CANAVANINE GLYCINE BROMOTHYMOL BLUE (CGB) MEDIUM  
Solution A 
Glycine                                                                        10gm 
Potassium dihydrogen orthophosphate                         1gm 
Magnesium sulphate                                                     1gm 
L- canavanine sulphate                                                30µg 
Thiamine hydrochloride                                                1µg 
Distilled water                                                             100ml 
Adjust pH to 5.6 + 0.2 and filter sterilize 
Solution B 
Bromothymol blue                                                       0.4gm 
Sodium hydroxide (NaOH) 0.01M                              64ml 
Distilled water                                                             36ml 
           Add 2ml of solution B to 88ml of distilled water. Add 2 gms agar and autoclave at 
1210C for 15 minutes. Cool to 550C and add 10ml of solution A. Mix well and pour in 
tubes/plates. 
 
  
5. CREATININE DEXTROSE BROMOTHYMOL BLUE THYMINE (CDBT) 
MEDIUM  
Solution A 
Creatinine                                                                     1gm 
Potassium dihydrogen orthophosphate                         1gm 
Magnesium sulphate                                                     0.5gm 
Dextrose                                                                        0.5gm 
Thymine                                                                        0.1gm 
Distilled water                                                              980ml 
Adjust pH to 5.6 and filter sterilize 
Solution B 
Bromothymol blue                                                       0.4gm 
Sodium hydroxide (NaOH) 0.01M                              64ml 
Distilled water                                                             36ml 
pH: 5.6 + 0.2 
           Mix solution A and 20ml of solution B. Add 20 gms agar and autoclave at 1210C 
for 15 minutes. Cool to 550C and pour in plates. 
 
 
 
APPENDIX- II 
 
  
 
APPENDIX- III (PROFORMA) 
¤ Name :                                                                       IP no: 
¤ Age/ Sex:                                                                  Ward: 
¤ Occupation: 
¤ Address: 
 
¤ Presenting complaints: 
COMPLAINT DURATION 
Fever  
Headache  
Nausea/vomiting  
Drowsiness  
Visual disturbances  
Others  
        
¤ Past history of similar episode: 
¤ H/O T.Fluconazole administration? 
 
¤ HIV status & duration: 
¤ Whether on ART: 
¤ CD4 count (at the time of presentation with meningitis) : 
¤ Associated comorbid illness 
 
¤ Physical examination: 
                 Fever 
            Neck stiffness 
            Altered sensorium 
            Signs of meningeal irritation 
            Focal neurological deficit 
            Papilledema (Fundus examination) 
 
¤ Treatment received by the patient for the current episode: 
¤ Follow up:  
 
 
 
¤ Laboratory Evaluation: 
 
CSF Sugar 
CSF Protein  
CSF Cell count 
 
India ink preparation 
Gram stain 
 
Latex Agglutination Test (LAT) 
 
Culture- SDA 
- Caffeic acid agar 
- CGB medium 
- CDBT medium 
 
           Urea hydrolysis 
            
          Assimilation of carbohydrates 
- Dextrose  
- Inositol 
- Lactose  
- Maltose 
- Sucrose 
- Cellobiose 
 
         Antifungal susceptibility testing  
 
 BROTH DILUTION E TEST 
MIC S/S-DD/R MIC S/S-DD/R 
Amphotericin-B     
Fluconazole     
Voriconazole    - - 
 
  
APPENDIX IV- PATIENT CONSENT FORM 
 
CRYPTOCOCCAL MENINGITIS IN HIV/AIDS PATIENTS
 O.P. No. Age Sex Fever
Heada
che
Vomitin
g
Alt.sen
sorium
Neck 
stiff
Papille
dema Other symp
Associated 
illness HIV dur On ART
CD4 
count
Rx 
T.Fluc Relapse Drug Rx Dur of Rx Follow up CSF- S/P/C India ink Gram stain LAT SDA Urease  CFA CGB CDBT
AM-B 
(MBD)
AM-B           
(E test)
FLU 
(MBD)
FLU            
(E TEST) VOR (MBD)
1
123604/
11 23 M No Yes No Yes No No Cough+ PT 3years Yes 439 No No Ceftriax 3days Survived 23/234/58 Neg
moderate 
pus cells+ Neg NG NA NA NA NA NA NA NA NA NA
2
412902/
12 36 M No Yes No No No No Nil Nil 2years No
not 
tested No No Ceftriax 7days Survived 73/39/0 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
3
155903/
12 30 M No Yes No Yes No No Nil Nil 5years yes 34 Yes No Amp-B 2days Survived
10/148/6
5 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
4
285004/
03 30 F Yes Yes Yes No No No Nil diarrhoea 3years Yes 118 Yes No ceftriax 5days Survived 55/37/7 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
5 37890 22 F No No Yes Yes Yes No Cough+ PTB 2years No 141 No No
Ceftriax, 
DOTS 3days Survived 36/20/- Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
6
398202/
12 45 M Yes Yes No No No No Nil Nil 5years yes 140 Yes No ceftriax 3days Survived 41/39/- Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
7
212004/
12 37 F No Yes Yes No No No limb paresis Nil 3years Yes 85 Yes No ceftriax 3days Survived 50/-/5 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
8
634306/
09 30 F Yes Yes Yes No No No Nil Nil 2years No 264 No No ceftriax 3days Survived 36/20/- Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
9
184104/
12 30 M Yes Yes Yes Yes No No
Cough, 
hemoptysis+
ATT default, 
oral thrush 3years Yes 19 Yes No ceftriax 3days Survived 55/37/7 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
10
349904/
12 42 M Yes Yes Yes Yes Yes No Nil
Left 
hemianopia
Newly 
diag No 128 No No ceftriax 3days Survived
10/148/6
5 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
11
100202/
12 27 M No No Yes Yes Yes No cough PTB 2years No 151 No No ceftriax 5days Survived 30/142/48 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
12 26895 45 M Yes Yes Yes No No No cough PTB 2years Yes 54 No No Amp-B 3days Died 12/44/- pos
pus cells+, 
YLO Positive
growth 
(72 hrs) Pos Brown col Growth + NA 0.5 0.5 2 8 0.5
13
60506/1
2 32 F No Yes No Yes No No Nil Nil 6months No 121 No No Ceftriax 3days Survived 30/142/48 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
14
176306/
12 38 M Yes No No Yes No No Nil Nil 2years Yes 224 No No Ceftriax 5days Survived 36/20/- Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
15
421611/
2010 25 M No Yes Yes No No No Nil Nil 2years No 267 No No Ceftriax 5days Survived 32/21/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
16
157807/
12 25 F No Yes Yes No No No Nil Nil 2years Yes 198 No No Ceftriax 5days Survived 18/40/I Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
17
673803/
04 35 M No Yes No Yes No No Nil Nil 2years Yes 302 No No Ceftriax 5days Survived 30/142/48 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
18
542807/
05 35 M No Yes No Yes No No Nil Nil 2years Yes 121 No No Ceftriax 5days Survived 36/20/- Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
19
148307/
12 31 M Yes No Yes No No No Nil Nil 6months No 148 No No Ceftriax 3days Survived
10/148/6
5 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
20
48008/1
2 28 F Yes No No Yes No No cough Nil 2years Yes 498 No No
Ceftriax, 
DOTS 3days Survived 23/234/58 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
21 29701 39 M No Yes No Yes No No Nil No 3 yrs No 63 No No Am-B 10days Survived 42/20/12 Pos
many pus 
cells, YLO Positive
Growth 
(48hrs) Pos Brown col NG NG 0.25 0.12 0.5 1 0.12
22
164605/
12 28 F Yes Yes No No No No cough PTB 2years Yes 29 No No
Ceftriax, 
DOTS 5days Died 32/21/4 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
23
48008/1
2 28 M No No Yes Yes No No Nil Nil 2years Yes 316 No No Ceftriax 3days Survived 40/26/8 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
24
195308/
12 25 M No Yes No Yes No No Nil Nil 2years Yes 287 No No Ceftriax 3days Survived 32/21/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
25
48008/1
2 28 F No No Yes Yes No No Nil Nil 2years Yes 269 No No Ceftriax 3days Survived 30/142/48 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
26
235804/
12 28 M Yes Yes Yes Yes Yes No cough  dyspnea oral thrush 4years Yes 43 Yes No Ceftriax 5days Died 23/377/- Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
27 89224 17 F Yes Yes Yes Yes No No Nil nil 3yrs NA
not 
tested NA No Ceftriax 5days Survived 32/21/4 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
28 109400 14 M No Yes Yes No Yes No Nil No 14yrs No 399 NA No Ceftriax 4days Survived 46/20/8 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
29 109700 32 M No Yes No Yes No No Nil PTB 5yrs No 410 NA No Ceftriax 5days Survived 39/21/6 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
30 1009 42 M No Yes No Yes No No FND+ No 3yrs No 388 NA No Ceftriax 3days Survived 46/28/2 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
31 20708 24 F Yes Yes Yes No No No Nil Nil 6months No 397 No No Ceftriax 5days Survived 48/16/5 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
32 36590 36 F Yes Yes No Yes Yes No Nil diarrhoea 2yrs No 278 No No Ceftriax 5days Survived 28/32/12 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
33
470409/ 
05 31 M No Yes Yes No No No Cough+ PT 7years Yes 208 No No
Cat II 
DOTS, 
Amp-B 5days Survived 30/183/18 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
34
367512/
10 30 M No Yes No No No No Nil Nil 2years No 659 No No Ceftriax 5days Survived 46/16/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
35
393302/
12 29 F Yes Yes No No No No Nil Nil 2years No
not 
tested No No Ceftriax 5days Survived 30/139/- Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
36
67703/ 
05 29 M Yes Yes No No No No Cough+ PT 7years Yes 11 Yes No Amp-B 3days Died 60/64/38 Neg
occ. pus 
cells+ Neg NG NA NA NA NA NA NA NA NA NA
CRYPTOCOCCAL MENINGITIS IN HIV/AIDS PATIENTS
37
203303/ 
07 36 M Yes Yes Yes No No No Cough+
Oral ulcers, 
Thrush, Cerv. 
LAD 5years Yes 618 Yes No Cat I DOTS 5days Survived 64/28/6 Neg
occ. pus 
cells+ Neg NG NA NA NA NA NA NA NA NA NA
38 91488 65 M Yes Yes Yes Yes Yes No Thrush DM 2yrs Yes 176 NA No Ceftriax 1day Died 16/34/I Neg
many pus 
cells,gpc 
pairs Negative NG NA NA NA NA NA NA NA NA NA
39
185412/ 
11 28 M Yes Yes No No No No Nil Nil 3yrs yes 56 no No Amp-B 10days Survived 36/82/22 pos
pus cells+, 
YLO Positive
growth 
(24 hrs) Pos Brown col NG NA 0.25 0.12 1 2 0.12
40
87903/1
1 41 M No No Yes Yes No No cough
pleural 
effusion 3yrs No 411 No No
Ceftriax, 
DOTS 5days Survived 30/142/48 Neg
occ. pus 
cells Neg NA NA NA NA NA NA NA NA NA
41
47103/ 
12 41 M Yes No No Yes No No Cough+ Thrush+ 2years Yes 299 Yes No Amp-B 2days Survived 48/65/- Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
42
420602/ 
12 55 M Yes No No Yes No No Cough+
B/L 
nephropathy
Newly 
diag No 74 Yes No Amp-B 1day Survived 85/24/0 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
43
144904/ 
11 35 M No Yes No Yes No No Nil Nil 2years Yes 99 No No Cat I DOTS 5days Survived
13/227/ 
108 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
44 29701 39 M Yes Yes Yes No Yes No skin lesions oral thrush 3 yrs No 32 default Yes Amp-B 2days Died 38/40/11 pos
many pus 
cells, YLO Positive
Growth 
(48 hrs) Pos Brown col NG NG 0.25 0.12 0.5 4 0.06
45
95003/ 
12 45 M Yes Yes No No No No Nil Nil 3years Yes 28 Yes No Ceftriax 5days Survived 53/48/42 Neg
occ. pus 
cells+ Neg NG NA NA NA NA NA NA NA NA NA
46
147406/
12 45 M No No Yes Yes No No cough Nil 3years No 172 No No ceftriax 5days Survived 32/21/4 Neg
occ. pus 
cells+ Neg NG NA NA NA NA NA NA NA NA NA
47
214903/
08 37 M Yes No Yes No No No cough Nil 3years No 213 No No ceftriax 5days Survived 40/26/8 Neg
occ. pus 
cells+ Neg NG NA NA NA NA NA NA NA NA NA
48
224203/
12 33 M Yes Yes No Yes No No
Cough, 
hemoptysis+
PT with PE, 
Abd TB, Oral 
ulcers,thrush 1year No
not 
tested Yes No
Ceftriax, 
DOTS 3days Died 32/31/2.3 Neg
moderate 
pus cells+ Neg NG NA NA NA NA NA NA NA NA NA
49
100403/
12 42 M No Yes No No No No Nil Nil 1year No 338 No No ceftriax 3days Survived 24/42/4 Neg
occ. pus 
cells+ Neg NG NA NA NA NA NA NA NA NA NA
50
116702/
11 41 M Yes Yes No No No No Nil diarrhoea 2years yes 137 No No cotrimox 3days Survived 59/33/12 Neg
occ. pus 
cells+ Neg NG NA NA NA NA NA NA NA NA NA
51
290403/
12 45 M No Yes Yes No No No Nil Nil 2years No 262 No No ceftriax 7days Survived 30/142/48 Neg
occ. pus 
cells+ Neg NG NA NA NA NA NA NA NA NA NA
52
306503/
12 27 M Yes Yes Yes No No No Nil ATT default 2years yes 115 Yes No ceftriax 7days Survived 40/102/- Neg
occ. pus 
cells+ Neg NG NA NA NA NA NA NA NA NA NA
53
304203/
12 33 M Yes Yes Yes No Yes No
limb paresis, 
GTCS
Oral ulcers, 
Thrush 5years yes 59 Yes No Amp-B 6days Died 49/38/22 Neg
occ. pus 
cells+ Neg NG NA NA NA NA NA NA NA NA NA
54
159103/
12 37 M No Yes Yes No No No Nil Nil 2years No
not 
tested No No ceftriax 7days Died 52/48/12 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
55
136302/
12 31 F Yes Yes Yes No No No Nil Nil 4years yes 42 No No Amp-B 10 days Survived 59/53/11 Neg
moderate 
pus cells Positive NG NA NA NA NA NA NA NA NA NA
56
160004/ 
12 22 M Yes Yes Yes No No No Nil Nil 1year No
not 
tested No No ceftriax 2days Died 30/142/48 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
57
160604/
12 35 M No Yes Yes No No No Nil Nil 4years Yes 110 Yes No ceftriax 7days Survived 40/26/8 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
58
195606/
12 33 M Yes No No Yes No No cough PTB 6months No 235 No No ceftriax 5days Survived 59/33/12 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
59
78306/ 
08 32 M No Yes Yes No No No FND+ On ATT 1year No 333 No No ceftriax 7days Survived 71/38/- Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
60
344906/
11 30 M Yes Yes Yes No No No Nil Nil 2years No 298 No No ceftriax 7days Survived 41/86/0 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
61
76106/1
2 38 M Yes No No Yes Yes No cough PTB 3years Yes 31 No No ceftriax 5days Died 59/33/12 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
62 32485 38 F No Yes Yes Yes No No
Blurring of 
vision PTB 1yr Yes 35 No No Am-B 2days Died 40/26/8 Pos
moderate 
pus cells Positive
Growth 
(48hrs) Pos Brown col NG NG 0.25 0.25 1 2 0.12
63 1003/11 47 M Yes Yes Yes No No No cough  dyspnea On ATT 3years Yes 129 Yes No
Ceftriax, 
DOTS 5days Survived 23/234/58 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
64
306503/
12 27 F No Yes Yes Yes No No Nil On ATT 2years No 115 No No
Ceftriax, 
DOTS 7days Survived 70/101/50 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
65
136206/
11 43 M Yes Yes Yes No No No cough  dyspnea oral thrush 4years Yes
not 
tested No No Ceftriax 5days Died not tested Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
66 116181 33 M No Yes No Yes Yes No paraparesis oral thrush On adm No 34 No No Ceftriax 2days Died 40/20/4 Neg
Many pus 
cells Positive
Growth 
(72 hrs) Pos brown col NG NG 0.5 0.12 0.5 1 0.12
67
393001/
07 34 M Yes Yes Yes No No No FND+
ATT default, 
oral thrush 3years Yes 51 Yes No
Ceftriax, 
DOTS 7days Died 23/234/58 Neg pus cells+ Neg NG NA NA NA NA NA NA NA NA NA
68
73807/ 
10 38 M Yes No No Yes No No cough  dyspnea
ATT default, 
oral thrush 4years Yes 40 Yes No
Ceftriax, 
DOTS 5days Died 65/329/8 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
69
263304/
12 34 M Yes Yes Yes No No No
Cough, 
hemoptysis+
PT with PE, 
Oral ulcers, 
Thrush 4years Yes
not 
tested Yes No Ceftriax 5days Died 43/65/3 Neg pus cells+ Neg NG NA NA NA NA NA NA NA NA NA
70
162604/
12 28 M No Yes Yes Yes No No Nil Nil
Newly 
diag No 89 No No Ceftriax 7days Survived 23/234/58 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
71
266404/
12 30 M No Yes Yes No No No FND+ On ATT 2years No 41 Yes No
Ceftriax, 
DOTS 7days Died 59/33/12 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
72
268204/
12 55 M Yes Yes No No No No Nil Nil 3years Yes 141 No No Ceftriax 3days Survived 40/20/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
CRYPTOCOCCAL MENINGITIS IN HIV/AIDS PATIENTS
73
181604/
12 38 M Yes Yes Yes No No No Nil Nil 3years Yes 189 No No Ceftriax 5days Survived 23/234/58 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
74
316404/
12 28 F No Yes No Yes No No Nil On ATT 3years Yes 208 No No
Ceftriax, 
DOTS 7days Survived 43/65/3 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
75
331604/
12 26 F Yes Yes Yes No No No Nil On ATT 3years Yes 306 No No
Ceftriax, 
DOTS 7days Survived 59/33/12 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
76
303504/
12 30 M No Yes Yes No No No FND+ ATT default 6months No 33 No No
Ceftriax, 
DOTS 7days Died 40/20/4 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
77
55107/ 
02 29 M Yes Yes No No No No Nil diarrhoea 10years Yes 125 Yes No Ceftriax 5days Survived 61/50/24 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
78
19205/ 
12 30 M No Yes Yes No No No FND+ On ATT 2years No 221 No No
Ceftriax, 
DOTS 5days Survived 23/234/58 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
79
185412/ 
11 28 M Yes Yes Yes Yes No No Nil Nil 3years Yes 151 Yes Yes Amp-B 7days Survived 30/142/48 Positive
Occ pus 
cells Positive NG NA NA NA NA NA NA NA NA NA
80 1003/11 47 M Yes Yes Yes No No No cough  dyspnea On ATT 3years Yes 129 Yes No
Ceftriax, 
DOTS 5days Survived 36/20/- Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
81
226205/
12 35 M No No Yes Yes No No cough PTB 2years Yes 50 No No
Ceftriax, 
DOTS 5days Died 59/33/12 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
82
303504/
12 30 M Yes No No Yes No No Nil Nil 2years Yes 455 No No Ceftriax 5days Survived 23/234/58 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
83
182405/
12 26 M Yes No Yes No No No Nil Nil 6months No 128 No No Ceftriax 5days Died 26/24/8 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
84
273705/
12 39 F No No Yes Yes No No Nil Nil 4years Yes 290 Yes No Ceftriax 5days Survived 43/65/3 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
85
300805/
12 43 M Yes No No No No No Nil Nil 3yrs No 67 No No Ceftriax 5days Died
10/148/6
5 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
86
36206/1
2 38 M No No Yes Yes No No Nil Nil 2years Yes 31 No No Ceftriax 5days Died 40/20/4 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
87 1003/11 47 M Yes No No Yes Yes No Nil Nil 3yrs No 106 No No Ceftriax 7days Survived 23/234/58 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
88
362908/ 
08 43 M No Yes Yes No No No Nil Nil 5years No 9 Yes No Amp-B 17days Survived 36/70/24 Positive
Occ pus 
cells, YLO Positive
growth 
(24 hrs) Pos brown col NG NG 0.25 0.032 1 2 0.12
89
296002/
10 39 M No No Yes Yes No No cough PTB on adm No 128 No No
Ceftriax, 
DOTS 10days Survived 36/20/- Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
90
361005/
12 39 M No Yes No Yes No No Nil Nil 3yrs Yes 277 No No Ceftriax 7days Survived 26/24/8 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
91
78106/1
2 30 M Yes No Yes No No No Nil Nil 3yrs Yes
not 
tested No No Ceftriax 3days Died 23/234/58 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
92
160206/
12 31 F No No Yes Yes No No Nil Nil 3yrs Yes 243 No No Ceftriax 5days Survived 40/20/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
93
508108/ 
05 37 M No Yes Yes No Yes No Nil ATT default 7years Yes 32 Yes No Amp-B 10days Died 56/130/28 Positive
occ. pus 
cells+ Positive NG NA NA NA NA NA NA NA NA NA
94
168706/
12 28 M No No Yes Yes No No cough PTB 4years Yes 216 Yes No
Ceftriax, 
DOTS 10days Survived 18/40/I Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
95
176506/
12 27 M Yes No No Yes No No Nil Nil 2years Yes 300 No No Ceftriax 3days Survived 43/65/3 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
96
155706/
12 38 M No No Yes Yes Yes No Nil Nil 3yrs Yes 296 No No Ceftriax 5days Survived 36/20/- Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
97
166206/
12 36 M Yes No No Yes No No Nil Nil 3yrs Yes 207 No No Ceftriax 3days Survived 26/24/8 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
98
376705/
12 35 M No Yes No Yes No No Nil Nil 3yrs Yes 149 No No Ceftriax 5days Survived 40/20/4 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
99
130706/
12 35 M No No Yes Yes No No cough PTB 4years Yes 156 Yes No
Ceftriax, 
DOTS 10days Survived 23/234/58 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
100
174403/ 
12 34 M No Yes yes No Yes No visual dist+
Thrush, Eso 
candidiasis+ 2mon
Yes, 
1mon 31 No No Amp-B 4days Died
29/132/ 
28 Positive
moderate 
pus cells Positive
Growth 
(48 hrs) Pos brown col NG NG 0.25 0.064 0.5 8 0.12
101
176506/
12 26 M No No Yes Yes No No cough PTB 4years No 98 Yes No
Ceftriax, 
DOTS 10days Survived 43/65/3 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
102
250506/
12 24 M Yes No No Yes No No cough PTB on adm No 187 No No
Ceftriax, 
DOTS 10days Survived 23/234/58 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
103
95208/1
0 31 F No Yes No Yes No No Nil Nil 4years Yes 234 No No Ceftriax 3days Survived 38/26/3 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
104
252706/
12 29 M Yes No No Yes No No Nil Nil 3yrs Yes 203 No No Ceftriax 3days Survived 40/20/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
105
243306/
12 36 M Yes No No Yes No No Nil Nil 3yrs Yes 311 No No Ceftriax 3days Survived 23/234/58 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
106
76507/1
1 28 F No No Yes Yes No No Nil oral thrush 3yrs Yes 49 No No Amp-B 3days Died 43/65/3 Neg Few YLO Neg
Growth 
(24 hrs) Neg white col NA NA NA NA NA NA NA
107
267606/
12 38 M Yes No No Yes No No Nil Nil 6months No 296 No No Ceftriax 5days Survived 36/20/- Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
108
100403/
12 42 M No No Yes Yes No No cough PTB 4years No 303 Yes No
Ceftriax, 
DOTS 10days Survived 40/20/4 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
109
85204/ 
12 44 M No No No Yes No No
L hemiparesis, 
urine 
incontinence oral thrush
Newly 
diag No 34 No No Amp-B 10days Survived 47/65/108 positive pus cells+ positive
Growth 
(72 hrs) Pos brown col NG NG 0.25 0.064 1 4 0.06
CRYPTOCOCCAL MENINGITIS IN HIV/AIDS PATIENTS
110
316706/
12 35 M No Yes Yes No No No Nil Nil 1yr No 199 No No Ceftriax 5days Survived 18/40/I Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
111
181206/
12 28 M Yes Yes No No No No Nil Nil 4years Yes 160 Yes No Ceftriax 5days Survived 23/234/58 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
112
93306/1
2 35 M No Yes No Yes No No Nil oral thrush 4years Yes 304 Yes No Ceftriax 5days Survived 43/65/3 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
113
199905/
12 33 F Yes No No Yes No No Nil oral thrush 4years Yes 331 No No Ceftriax 5days Survived 38/26/3 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
114
176506/
12 45 M Yes Yes No No No No Nil Nil 2years Yes 295 No No Ceftriax 3days Survived 40/20/4 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
115
40904/1
1 27 M No No Yes Yes No No Nil Nil 2years No 128 No No Ceftriax 3days Survived 23/234/58 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
116
183906/
12 38 M No No Yes Yes No No Nil Nil 2years No 404 No No Ceftriax 3days Survived 38/26/3 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
117
307306/
11 28 M Yes Yes No No No No Nil Nil 2years Yes 386 No No Ceftriax 3days Survived
10/148/6
5 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
118
86101/1
2 26 F No No Yes No No No Nil Nil 2years Yes 179 No No Ceftriax 5days Survived 40/20/4 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
119
40704/1
2 25 M No Yes No No No No Nil Nil 2years Yes 241 No No Ceftriax 5days Survived 43/65/3 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
120
156407/
12 45 M Yes Yes No No No No cough PTB 4years Yes 32 Yes No
Ceftriax, 
DOTS 10days Died 38/26/3 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
121
176506/
12 28 M Yes Yes No No Yes No Nil Nil 1yr No 209 No No Ceftriax 5days Survived 28/32/12 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
122
325503/
12 40 M No No Yes No No No Nil Nil on adm No 29 No No Ceftriax 3days Died 26/24/8 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
123
82609/1
2 35 M No No Yes No No No Nil Nil 2years Yes 179 No No Ceftriax 5days Survived 40/20/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
124
246207/
12 37 M Yes Yes No No No No Nil Nil 4years Yes 154 No No Ceftriax 3days Survived 43/65/3 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
125
176506/
12 40 M No No Yes No No No Nil Nil 2years Yes 138 No No Ceftriax 5days Survived 61/50/24 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
126
333907/
12 39 M Yes Yes Yes No No No Nil Nil 4years Yes 285 No No Ceftriax 5days Survived 38/26/3 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
127
334987/
12 42 M No Yes Yes No No No Nil Nil 1yr No 314 No No Ceftriax 3days Survived 38/26/3 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
128
335207/
12 43 M No Yes Yes No No No Nil Nil 2years Yes 308 No No Ceftriax 5days Survived 40/20/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
129
145406/
12 33 F No No Yes No No No cough PTB 4years No 267 Yes No
Ceftriax, 
DOTS 10days Survived 26/24/8 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
130
220803/
12 43 M No Yes Yes No No No Nil PTB 2years Yes
not 
tested Yes No
Cat II 
DOTS, 
Amp-B 1day Died 43/65/3 Neg
occ. pus 
cells, YLO Positive NG NA NA NA NA NA NA NA NA NA
131
283611/
07 35 M No No Yes Yes No No cough PTB 1yr No 12 No No
Ceftriax, 
DOTS 10days Died 28/32/12 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
132 99891 25 F No No Yes Yes No No Nil nil 3 yrs no 56 no No Amp-B 7days Survived 44/60/22 Neg Neg Positive
Growth        
(5 days) pos brown col NG NG 0.12 0.016 2 8 0.06
133
145406/
12 33 M Yes Yes Yes No No No cough PTB 2years Yes 217 No No
Ceftriax, 
DOTS 10days Survived 38/26/3 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
134
41208/1
2 43 M Yes Yes No No No No Nil Nil 2years Yes 187 No No Ceftriax 5days Survived 61/50/24 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
135
79308/1
2 37 F No No Yes Yes No No Nil Nil on adm No 456 No No Ceftriax 3days Survived 38/26/3 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
136
102908/
12 38 M Yes Yes Yes No No No Nil Nil 1yr No 237 No No Ceftriax 5days Survived 28/32/12 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
137
114208/
12 44 M No No Yes Yes Yes No Nil Nil 2years Yes 296 No No Ceftriax 3days Survived 40/20/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
138
224207/
12 29 M No Yes Yes No No No Nil Nil 2years Yes 302 No No Ceftriax 5days Survived 38/26/3 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
139
151708/
12 37 M No Yes No Yes No No Nil Nil 2years Yes 169 No No Ceftriax 3days Survived 28/32/12 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
140
322807/
08 32 F No No Yes Yes No No cough PTB 2years Yes 185 No No
Ceftriax, 
DOTS 10days Survived 26/24/8 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
141 1407/12 42 M Yes Yes No No No No cough PTB 6months No 219 No No
Ceftriax, 
DOTS 10days Survived 40/20/4 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
142
121604/
04 44 M Yes No No Yes Yes No Nil Nil on adm No 220 No No Ceftriax 5days Survived 38/26/3 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
CRYPTOCOCCAL MENINGITIS IN HIV/AIDS PATIENTS
143
194508/
12 30 M No Yes Yes No No No Nil Nil 1yr Yes 308 No No Ceftriax 3days Survived 28/32/12 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
144
126108/
04 36 M No Yes Yes No No No Nil Nil 1yr Yes 367 No No Ceftriax 3days Survived
10/148/6
5 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
145
514205/
05 47 M No Yes Yes No No No cough PTB 2years No 289 No No
Ceftriax, 
DOTS 10days Survived 61/50/24 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
146
226808/
12 45 M No Yes Yes No No No Nil Nil 1yr No 198 No No Ceftriax 5days Survived 40/20/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
147
169604/
12 42 M Yes Yes No No No No Nil oral thrush 3mon No 115 No No Amp-B 10days Survived
13/183/   
205 Neg No pus cells positive NG NA NA NA NA NA NA NA NA NA
148
129112/
08 32 F Yes Yes Yes No No No visual dist+ Nil 1yr No 202 No No Ceftriax 5days Survived 26/24/8 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
149
237608/
12 28 M Yes Yes No No No No Nil Nil 2years No 219 No No Ceftriax 3days Survived 40/20/4 Neg No pus cells Neg NG NA NA NA NA NA NA NA NA NA
150
315608/
12 24 F No No Yes No No No Nil Nil 2years Yes 312 No No Ceftriax 3days Survived 38/26/3 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
151
114208/
12 44 M No No No Yes No No Nil Nil 2years Yes 176 No No Ceftriax 5days Survived 61/50/24 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
152
291301/
05 42 M Yes Yes Yes No No No Nil Nil 2years Yes
not 
tested No No Ceftriax 3days Died 40/20/4 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
153
68404/1
2 28 M No Yes Yes No No No Nil Nil 2years Yes 160 No No Ceftriax 3days Died 38/26/3 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
154
293611/
11 38 F No Yes No Yes No No visual dist+ Nil 2years Yes 401 No No Ceftriax 5days Survived 40/20/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
155
327507/
12 22 M No Yes Yes Yes Yes No Nil oral thrush on adm No 25 No No Amp-B 2 days Died 36/43/- Positive
many pus 
cells, YLO Positive
Growth 
(48 hrs) Pos Brown col NG NG 0.25 0.032 1 4 0.12
156
66709/1
0 40 M Yes Yes No No No No Nil Nil 2years Yes 24 No No Ceftriax 3days Survived 26/24/8 Neg
occ. pus 
cells Positive Growth + NA NA NA NA NA NA NA NA NA
157
126108/
04 36 M Yes No Yes No No No Nil Nil 6months No 210 No No Ceftriax 5days Survived 38/26/3 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
158
546207/
06 46 M No Yes Yes No No No Nil Nil 1yr No 145 No No Ceftriax 3days Survived 61/50/24 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
159
362908/ 
08 43 M Yes Yes Yes No No Yes visual dist+ Nil 5years Yes 89 Yes Yes  Amp-B 7days Survived 74/67/50 Neg
moderate 
pus cells Positive NG NA NA NA NA NA NA NA NA NA
160
311403/
07 55 M No Yes No Yes No No Nil Nil 1yr No 139 No No Ceftriax 5days Survived 40/20/4 Neg
occ. pus 
cells Neg NG NA NA NA NA NA NA NA NA NA
161 32882 40 M Yes Yes No No No No Nil Nil 6months No 297 No No Ceftriax 5days Survived 44/18/8 Neg No pus cells Negative NG NA NA NA NA NA NA NA NA NA
162 72682 22 M No Yes No Yes No No Nil No 1yr No 312 NA No Ceftriax 3days Survived 46/20/6 Neg No pus cells Negative NG NA NA NA NA NA NA NA NA NA
163 84772 45 M Yes Yes Yes No No No Thrush DM 2yrs Yes 289 NA No Ceftriax 3days Survived 36/20/- Neg No pus cells Negative NG NA NA NA NA NA NA NA NA NA
164 86985 39 M No Yes No Yes Yes Yes Nil diarrhoea 2 1/2yrs Yes 31 Yes Yes Am-B 2days Died 18/40/I Pos
moderate 
pus cells Positive 48hrs NA NA NA NA NA NA NA NA NA
165
201007/
12 41 M No Yes No No No No
paraparesis, 
blurring vision, 
fits (GTCS) Nil 2 yrs Yes 24 Yes No Amp-B 10 days Survived 19/34/26 Positive
moderate 
pus cells Positive
Growth (7 
days) Pos Brown col NG NG 0.12 0.016 0.5 1 0.06
166 91235 17 M Yes No Yes No No No Seizure Nil 17yrs Yes 194 No No Ceftriax 4days Survived 50/24/4 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
167 98761 28 M No Yes No Yes No No Nil 6months No 485 No No Ceftriax 3days Survived 44/23/2 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
168 109984 39 M Yes Yes Yes No Yes No Nil No 2yrs No 376 No No Ceftriax 5days Survived 18/30/I Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
169
92432/1
2 23 F Yes Yes No No No No Nil Nil 2years Yes 36 No No Ceftriax 5days Died
10/148/6
5 Neg
moderate 
pus cells Neg NG NA NA NA NA NA NA NA NA NA
170
93107/1
1 41 M Yes Yes No No No No
swelling Left  
wrist PTB 2yrs Yes 62 no No Am-B 7days Survived 61/50/24 Pos
Pus cells, 
YLO Positive
Growth 
(72hrs) Pos Brown col NG NG 0.25 0.032 1 4 0.25
171 28939 40 M No Yes Yes Yes Yes No Nil Nil 2years Yes 99 No No Ceftriax 3days Survived 45/32/12 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
172 33955 55 M Yes Yes No No No No FND+ Nil 1yr No 301 No No Ceftriax 3days Survived 26/24/8 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
173 37029 39 M No Yes Yes No No No FND+ Nil 2yrs Yes 299 No No Ceftriax 3days Survived 38/26/3 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
174 37724 24 M Yes Yes No Yes No No Nil Nil on adm No 119 No No Ceftriax 2days Died 24/24/2 Neg
occ. pus 
cells Negative NG NA NA NA NA NA NA NA NA NA
175
100202/
12 27 F No No Yes Yes No No Nil Nil 2years Yes 151 No No Ceftriax 5days Survived 18/40/I Neg
moderate 
pus cells Negative NG NA NA NA NA NA NA NA NA NA
